<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0908233977
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CARVYKTI
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CILTACABTAGENE AUTOLEUCEL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100000000
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        TU/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Intravenous infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        70
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bag
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a freezer
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2409034.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Janssen Pharmaceuticals, Inc" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Janssen Pharmaceuticals, Inc
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            JANSSEN PHARMACEUTICA N.V
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CARVYKTI is a type of medicine called a &ldquo;genetically modified cell therapy&rdquo; which is made especially for you from your own white blood cells, called T cells.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CARVYKTI is used to treat adult patients with cancer of the bone marrow called multiple myeloma. It is given when at least one other treatment has not worked.</p><p>&nbsp;</p><p><strong>How CARVYKTI works</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The white blood cells taken from your blood are modified in the laboratory to insert a gene that allows them to make a protein called chimeric antigen receptor (CAR).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The CAR can attach to a specific protein on the surface of myeloma cells allowing your white blood cells to recognise and attack the myeloma cells.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You must not be given CARVYKTI</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to any of the ingredients of this medicine (listed in section&nbsp;6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to any of the ingredients in the medicines you will be given to reduce the number of white blood cells in your blood (lymphodepleting therapy) before treatment with CARVYKTI (see also section&nbsp;3, How CARVYKTI is given).</p><p>&nbsp;</p><p>If you think you may be allergic, ask your doctor for advice.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p><strong>&nbsp;</strong></p><p>Patients treated with CARVYKTI may develop new types of cancers. There have been reports of patients developing cancer, beginning in a type of white blood cells called T-cells, after treatment with CARVYKTI and similar medicines. Talk to your doctor if you experience any new swelling of your glands (lymph nodes) or changes in your skin such as new rashes or lumps.</p><p><strong>&nbsp;</strong></p><p>Tell your doctor before you are given CARVYKTI if you have:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; current or past problems with your nervous system - such as fits, stroke, new or worsening memory loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any lung, heart or blood pressure (low or raised) problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver or kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; signs or symptoms of graft-versus-host disease. This happens when transplanted cells attack your body, causing symptoms such as rash, nausea, vomiting, diarrhoea and bloody stools.</p><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your doctor before you are given CARVYKTI.</p><p>&nbsp;</p><p><strong>Tests and checks</strong></p><p><strong>Before you are given CARVYKTI your doctor will:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; check the levels of blood cells in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; check your lungs, heart and blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; look for signs of infection - an infection will be treated before you have CARVYKTI</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; check if your cancer is getting worse</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; check for hepatitis B, hepatitis C or HIV infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; check if you had a vaccination in the last 6&nbsp;weeks or plan to have one in the next few months.</p><p>&nbsp;</p><p><strong>After treatment with CARVYKTI your doctor will:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; regularly check your blood, as the number of blood cells and other blood components may decrease.</p><p>Tell your doctor right away if you get a fever, chills or any signs or symptoms of an infection, are feeling tired, or have bruising or bleeding.</p><p>&nbsp;</p><p><strong>Look out for serious side effects</strong></p><p>There are serious side effects which you need to tell your doctor or nurse about straight away and which may require you to get immediate medical attention. See section&nbsp;4 under &lsquo;Serious side effects&rsquo;.</p><p>&nbsp;</p><p><strong>Children and adolescents </strong></p><p>CARVYKTI should not be used in children and adolescents below 18&nbsp;years of age as the medicine has not been studied in this age group and it is not known if it is safe and effective.</p><p>&nbsp;</p><p><strong>Other medicines and CARVYKTI</strong></p><p>Before you are given CARVYKTI tell your doctor or nurse if you are taking, have recently taken, or might take any other medicines.</p><p>In particular, tell your doctor or nurse if you are taking:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that weaken your immune system such as corticosteroids.</p><p>These medicines may interfere with the effect of CARVYKTI.</p><p>&nbsp;</p><p><strong>Vaccines and CARVYKTI</strong></p><p>You must not be given certain vaccines called live vaccines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the 6&nbsp;weeks before you are given the short course of chemotherapy (called lymphodepleting chemotherapy) to prepare your body for the CARVYKTI cells.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; after CARVYKTI treatment while your immune system is recovering.</p><p>Talk to your doctor if you need to have any vaccinations.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before being given this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This is because the effects of CARVYKTI in pregnant or breast-feeding women are not known.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CARVYKTI may harm your unborn baby or your breast-fed child.</p><p>&nbsp;</p><p>If you are pregnant or think you may be pregnant after treatment with CARVYKTI, talk to your doctor immediately.</p><p>&nbsp;</p><p>You have to do a pregnancy test before treatment starts. CARVYKTI should only be given if the results show you are not pregnant.</p><p>&nbsp;</p><p>If you have had CARVYKTI treatment, you should discuss any plans to have future pregnancies with your doctor.</p><p>&nbsp;</p><p><strong>Driving and using tools or machines</strong></p><p>CARVYKTI can severely affect your ability to drive or use tools or machines causing side effects that may make you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feel tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have balance and coordination problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feel confused, weak or dizzy.</p><p>Do not drive or use tools or machines until at least 8&nbsp;weeks after having CARVYKTI and if these symptoms return.</p><p>&nbsp;</p><p><strong>CARVYKTI contains dimethyl sulfoxide (DMSO) and kanamycin</strong></p><p>This medicine contains DMSO (a substance used to preserve frozen cells) and may contain traces of kanamycin (an aminoglycoside antibiotic), both of which can sometimes cause allergic reactions. Your doctor will monitor you for any signs of a possible allergic reaction.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>CARVYKTI will always be given to you by a healthcare professional at a qualified treatment centre.</p><p>&nbsp;</p><p><strong>Making CARVYKTI from your own blood cells</strong></p><p>CARVYKTI is made from your own white blood cells. Your blood cells will be collected from you to prepare your medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will take some of your blood using a catheter (tube) placed in your vein.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some of your white blood cells are separated from your blood - the rest of your blood is returned to your vein. This process is called &lsquo;leukapheresis&rsquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This process can take 3 to 6&nbsp;hours and may need to be repeated.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your white blood cells are sent to the manufacturing centre where they are modified to make CARVYKTI. This process takes about 4&nbsp;weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; While CARVYKTI is made you may get other medicines to treat the multiple myeloma. This is so it does not get worse.</p><p>&nbsp;</p><p><strong>Medicines given before CARVYKTI treatment</strong></p><p><strong>&nbsp;</strong></p><p><strong>A few days before</strong> - you will be given treatment called &ldquo;lymphodepleting therapy&rdquo; to prepare your body to receive CARVYKTI. This treatment reduces the number of white blood cells in your blood, so the genetically modified white blood cells in CARVYKTI can grow in numbers when they are returned to your body.</p><p>&nbsp;</p><p><strong>30 to 60</strong>&nbsp;<strong>minutes before</strong> - you may be given other medicines. These may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antihistamine medicines for an allergic reaction - such as diphenhydramine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for fever - such as paracetamol.</p><p>Your doctor or nurse will check carefully that the CARVYKTI treatment you are given is from your own white blood cells.</p><p>&nbsp;</p><p><strong>How you are given CARVYKTI</strong></p><p>CARVYKTI is a one-time treatment. It will not be given to you again.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor or nurse will give you CARVYKTI by a drip into your vein. This is called an &lsquo;intravenous infusion&rsquo; and is usually less than 60&nbsp;minutes.</p><p>CARVYKTI is the genetically modified version of your white blood cells.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your healthcare professional handling CARVYKTI will take appropriate precautions to prevent the chance of transfer of infectious diseases.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; They will also follow local guidelines to clean up or dispose of any material that has been in contact with CARVYKTI.</p><p>&nbsp;</p><p><strong>After you are given CARVYKTI</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Plan to stay near the hospital where you were treated for at least 4&nbsp;weeks after you are given CARVYKTI.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will need to return to the hospital every day for at least 14&nbsp;days after you are given CARVYKTI. This is so your doctor can check if your treatment is working and treat you if you get any side effects. If you do develop serious side effects, you may need to stay in the hospital until your side effects are under control and it is safe for you to leave.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you miss any appointments, call your doctor or qualified treatment centre as soon as possible to make a new appointment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will be asked to enroll in a registry for at least 15&nbsp;years in order to monitor your health and better understand the long‑term effects of CARVYKTI.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Having CARVYKTI in your blood may cause some commercial HIV tests to incorrectly give you a HIV positive result even though you may be HIV negative.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not donate blood, organs, tissues or cells for transplants after you have had CARVYKTI.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>CARVYKTI can cause side effects that may be serious or life-threatening.</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p>Get medical help straight away if you get any of the following serious side effects which may be severe and can be fatal.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A serious immune reaction known as &lsquo;cytokine release syndrome (CRS)&rsquo;, some signs include:</p><p>&nbsp;</p><p><strong>Very common (</strong>may affect more than 1 in 10&nbsp;people):</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills, fever (38&nbsp;&deg;C or higher).</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heart beat, difficulty breathing,</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure which can make you feel dizzy or lightheaded.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effects on your nervous system, symptoms of which can occur days or weeks after you receive the infusion, and may initially be subtle. Some of these symptoms may be signs of a serious immune reaction called &lsquo;immune effector cell associated neurotoxicity syndrome&rsquo; (ICANS) or may be signs and symptoms of parkinsonism:</p><p>&nbsp;</p><p><strong>Very common</strong> (may affect more than 1 in 10&nbsp;people):</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling confused,</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; less alert, disorientated, anxious, memory loss,</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty speaking or slurred speech,</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slower movements, changes in handwriting</p><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1 in 10&nbsp;people):</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of coordination, affecting movement and balance,</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty reading, writing and understanding words,</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; personality changes, which may include being less talkative, disinterest in activities and reduced facial expression</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CARVYKTI may increase the risk of life-threatening infections that may lead to death.</p><p>&nbsp;</p><p>If you notice any of the above side effects, get medical help straight away.</p><p>&nbsp;</p><p><strong>Other side effects</strong></p><p>Other side effects are listed below. Tell your doctor or nurse if you get any of these side effects.</p><p>&nbsp;</p><p><strong>Very common</strong> (may affect more than 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infected nose, sinuses or throat (a cold)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bacterial infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough, being short of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pneumonia (lung infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; viral infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleep problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, including muscle and joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling caused by fluid build up in the body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling very tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea (feeling sick), decreased appetite, constipation, vomiting, diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems with movement including muscle spasms, muscle tightness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nerve damage that may cause tingling, numbness, pain or loss of pain sensation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of antibodies called immunoglobulins in the blood &ndash; which may lead to infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of oxygen in the blood causing shortness of breath, coughing, headache, and confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding, which can be severe, called a &lsquo;haemorrhage&rsquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal blood tests indicating:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of white blood cells (including neutrophils and lymphocytes)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of &lsquo;platelets&rsquo; (cells that help blood to clot) and red blood cells</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of calcium, sodium, potassium, magnesium, phosphate in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of &lsquo;albumin&rsquo; a type of protein in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clotting problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of a protein called &lsquo;ferritin&rsquo; in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of enzymes in the blood called &lsquo;gamma-glutamyltransferase&rsquo; and &lsquo;transaminases&rsquo;</p><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;allergic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of white blood cells (neutrophils), which can occur with infection and fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gastroenteritis (inflamed stomach and gut)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary tract infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fungal infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased number of a type of white blood cell (lymphocytes)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe infection throughout the body (sepsis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious immune reaction involving the blood cells - may lead to an enlarged liver and spleen, called &lsquo;haemophagocytic lymphohistiocytosis&rsquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious condition where fluid leaks out of the blood vessels into the body tissues called &lsquo;capillary leak syndrome&rsquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious problems caused by rapid breakdown of cancer cells (tumor lysis syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits (seizures)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of enzymes in the blood called &lsquo;alkaline phosphatase&rsquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle tremor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mild muscle weakness caused by nerve damage</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; falls</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; facial numbness, difficulty moving muscles of face and eyes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; double vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast eye movements that you cannot control</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high level of &lsquo;bilirubin&rsquo; in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clot</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stroke</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of a protein called &lsquo;C-reactive protein&rsquo; in the blood that may indicate an infection or inflammation</p><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect up to 1 in 100&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tingling, numbness, and pain of hands and feet, difficulty walking, leg and/or arm weakness, and difficulty breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A new type of cancer beginning in a type of white blood cells called T-cells (secondary malignancy of T-cell origin)</p><p>&nbsp;</p><p>Tell your doctor or nurse if you get any of the side effects listed above. Do not try to treat your symptoms with other medicines on your own.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The following information is intended for doctors only.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the container label and infusion bag after &lsquo;EXP&rsquo;.</p><p>Store frozen in vapour phase of liquid nitrogen (&le;&nbsp;-120&nbsp;&deg;C) until thawed for use.</p><p>Do not refreeze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What CARVYKTI contains</strong></p><p>The active substance is ciltacabtagene autoleucel.</p><p>&nbsp;</p><p>Each CARVYKTI infusion bag contains ciltacabtagene autoleucel cell dispersion containing 3.2&nbsp;&times;&nbsp;10<sup>6</sup>&nbsp;to&nbsp;1&nbsp;&times;&nbsp;10<sup>8</sup>&nbsp;CAR-positive viable T&nbsp;cells suspended in a cryopreservative solution.</p><p>An infusion bag contains 30&nbsp;mL or 70&nbsp;mL of dispersion for infusion.</p><p><em>&nbsp;</em></p><p>The other ingredients are a solution (Cryostor CS5) used to preserve frozen cells (see section&nbsp;2, CARVYKTI contains DMSO and kanamycin).</p><p>&nbsp;</p><p>This medicine contains genetically modified human cells.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                CARVYKTI is a colourless to white, including shades of white, yellow, and pink, 30 mL or 70 mL cell dispersion for infusion, supplied in either a 50 mL or a 250 mL infusion bag respectively, individually packed in an aluminium cryo cassette.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Janssen-Cilag International NV</p><p>Turnhoutseweg&nbsp;30</p><p>B-2340&nbsp;Beerse</p><p>Belgium</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Janssen Pharmaceuticals, Inc</p><p>1000 Route 202 South</p><p>Raritan, New Jersey 08869</p><p>USA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	To contact us, please visit our website  www.janssen.com/contact-us  
	
	This leaflet was last revised in July 2024.  

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&middot;&nbsp;&nbsp; كارفيكتي هو نوع من الدواء يسمى &quot; العلاج بالخلايا المعدلة وراثيا &quot;. والتي هي معدة خصيصاً لك من خلايا الدم البيضاء الخاصة بك تسمى &quot;خلايا T&quot; .</p><p dir="RTL">&middot;&nbsp;&nbsp; يستخدم كارفيكتي لعلاج المرضى البالغين المصابين بسرطان نخاع العظام المسمى بالمايلوما المتعددة. يتم إعطاء كارفيكتي &nbsp;عندما لا يعمل &nbsp;نوع واحد آخر على الأقل من العلاج.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>كيف يعمل </strong><strong>كارفيكتي</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;يتم تعديل خلايا الدم البيضاء المأخوذة من دمك في المختبر لإضافة الجين الذي يسمح لهذه الخلايا بأن تنتج بروتين يسمى مستقبِل مستضد الكيميري (CAR)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن ل(CAR) الارتباط ببروتين معين موجود على سطح خلايا المايلوما ليسمح لخلايا دمك البيضاء للتعرف على خلايا المايلوما ومهاجمتها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا</strong> <strong>يجب أن تتلقى</strong> <strong>&nbsp;</strong><strong>كارفيكتي</strong></p><p dir="RTL">&middot;&nbsp; إذا كان لديك حساسية من أي من مكونات هذا الدواء (المدرجة في القسم <strong>6</strong>).</p><p dir="RTL">&middot;&nbsp; إذا كنت تعاني من حساسية تجاه أي من مكونات الأدوية التي ستُعطى لك لتقليل عدد خلايا الدم البيضاء في دمك (لعلاج</p><p dir="RTL">&nbsp;المستنفذ للخلايا اللمفاوية)&nbsp; قبل العلاج بكارفيكتي (انظر أيضًا القسم 3 ، كيف يتم إعطاء كارفيكتي).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعتقد أنك لديك أي نوع من أنواع الحساسية، فاستشر طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">قد تتطور أنواع جديدة من السرطان لدى المرضى الذين عولجوا مع كارفيكتي. كانت هناك تقارير عن مرضى يصابون بالسرطان، بدءا من نوع من خلايا الدم البيضاء تسمى الخلايا <strong>T</strong>، بعد العلاج بكارفيكتي وأدوية مماثلة. تحدث إلى طبيبك إذا لاحظت أي تورم جديد في الغدد (الغدد الليمفاوية) أو تغييرات في بشرتك مثل الطفح الجلدي أو الكتل الجديدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك قبل أن يتم إعطاؤك كارفيكتي إذا كان لديك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل حالية أو سابقة في جهازك العصبي - مثل النوبات أو السكتة الدماغية أو فقدان الذاكرة الجديد أو المتفاقم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي مشاكل في الرئة أو القلب أو ضغط الدم (منخفض أو مرتفع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكبد أو الكُلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات أو أعراض من مرض graft-versus-host . هذا يحدث عندما تهاجم الخلايا المزروعة جسدك، مسببة أعراض مثل الطفح الجلدي والغثيان والتقيؤ والإسهال والبراز الدموي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان أي مما ذُكر أعلاه ينطبق عليك (أو لم تكن متأكدًا)، تحدث إلى طبيبك قبل أن يتم إعطاؤك كارفيكتي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاختبارات والفحوصات</strong></p><p dir="RTL"><strong>قبل أن يتم إعطاؤك</strong> <strong>كار</strong><strong>فيكتي سيقوم طبيبك بما يلي:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فحص مستويات خلايا الدم في دمك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فحص رئتيك وقلبك وضغط دمك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البحث عن علامات العدوى - سيتم علاج العدوى قبل أن يتم إعطاؤك كارفيكتي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التحقق مما إذا كان السرطان لديك يزداد سوءًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التحقق من وجود عدوى التهاب الكبد B أو التهاب الكبد C أو فيروس نقص المناعة البشرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التحقق مما إذا كنت قد تلقيت لقاحًا في الأسابيع الستة الماضية أو تخطط للحصول على لقاح في الأشهر القليلة المقبلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بعد العلاج بكارفيكتي ، سيقوم طبيب</strong><strong>ك</strong><strong> بما يلي:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فحص خلايا الدم بانتظام، حيث قد ينخفض عدد خلايا الدم أو مكونات الدم الأخرى.</p><p dir="RTL">أخبر طبيبك على الفور إذا كنت تعاني من حمى أو قشعريرة أو أي علامات أو أعراض للعدوى، أو تشعر بالتعب، أو تعاني من كدمات أو نزيف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ترقب الأعراض الجانبية الخطيرة</strong></p><p dir="RTL">هناك أعراض جانبية خطيرة يجب أن تخبر طبيبك أو ممرضتك عنها على الفور. والتي يمكن أن تتطلب منك الحصول على عناية طبية فورية. انظر القسم 4 تحت عنوان &quot;الأعراض الجانبية الخطيرة&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقين </strong></p><p dir="RTL">لا ينبغي استخدام كارفيكتي للأطفال والمراهقين<strong> </strong>دون سن 18 عامًا حيث أنه لم يتم دراسة هذا الدواء لهذه الفئة العمرية وليس معروفاً إذا كان آمناً وفعالاً.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى </strong>و<strong>كارفيكتي</strong></p><p dir="RTL">قبل أن يتم إعطاؤك كارفيكتي ، أخبر طبيبك أو ممرضتك إذا كنت تتناول، أو تناولت مؤخرًا، أو قد تتناول أي أدوية أخرى على وجه الخصوص، أخبر طبيبك أو ممرضتك إذا كنت تتناول:</p><p dir="RTL">&middot;&nbsp;&nbsp; &nbsp;&nbsp;أدوية من شأنها أن تضعف جهازك المناعي مثل الستيرويدات القشرية (corticosteroids).</p><p dir="RTL">قد تتداخل هذه الأدوية مع تأثير كارفيكتي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اللقاحات </strong>و<strong>كارفيكتي</strong></p><p dir="RTL">يجب ألا تتلقى لقاحات معينة تسمى اللقاحات الحية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في الأسابيع الستة التي تسبق إعطائك جرعة قصيرة الأمد من العلاج الكيميائي (والمسماة بالعلاج الكيميائي المستنفذ للخلايا اللمفاوية) لتحضير جسمك لخلايا كارفيكتي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد العلاج بكارفيكتي بينما يتعافى جهازك المناعي.</p><p dir="RTL">تحدث إلى طبيبك إذا كنت بحاجة إلى أي لقاحات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ &nbsp;حاملاً أو مرضعة، أو تعتقدين أنك حامل أو تخططين لإنجاب طفل، فاستشيري طبيبك قبل تلقي هذا الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هذا لأن الآثار المترتبة على &nbsp;العلاج بكارفيكتي غير معروفة في النساء الحوامل أو المرضعات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يؤذي كارفيكتي جنينك أو طفلك الرضيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت حاملاً أو تعتقدين أنك حامل بعد العلاج بكارفيكتي فتحدثي إلى طبيبك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تخضعين لاختبار الحمل قبل بدء العلاج. يجب إعطاء كارفيكتي فقط إذا أظهرت النتائج أنك لست حاملاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تناقشي أي قرار حمل مع طبيبك إذا كنت قد تلقيت العلاج بكارفيكتي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الأدوات أو الآلات</strong></p><p dir="RTL">يستطيع أن يؤثر كارفيكتي بشدة على القدرة على قيادة السيارة أو استخدام الأدوات أو الآلات مسبباً أعراض جانبية قد تجعلك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشعر بالتعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك مشاكل في التوازن والتنسيق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشعر بالارتباك أو الضعف أو الدوار.</p><p dir="RTL">لا تقم بالقيادة أو استخدام الأدوات أو الآلات خلال 8 أسابيع على الأقل بعد تلقي &nbsp;كارفيكتي وفي أي وقت تعاودك فيه هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي كارفيكتي على ثنائي ميثيل السلفوكسيد </strong><strong>(DMSO)</strong><strong> وكاناميسين</strong></p><p dir="RTL">يحتوي هذا الدواء على ثنائي ميثيل السلفوكسيد (DMSO) (مادة تستخدم لحفظ الخلايا المجمدة) وقد يحتوي على مقدار طفيف من الكاناميسين (مضاد حيوي من فئة الأمينوغليكوسيد (aminoglycoside)) وكلاهما يمكن أن يسببان أحيانًا ردود فعل تحسسية. سيقوم طبيبك بمراقبة أي علامات لرد فعل تحسسي محتمل.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;سيتم إعطاؤك كارفيكتي دائماً بواسطة اختصاصي رعاية صحية في مركزعلاج مؤهل.</p><p dir="RTL"><strong>تحضير كارفيكتي</strong> <strong>&nbsp;من خلايا الدم الخاصة بك</strong></p><p dir="RTL">يتم تحضير كارفيكتي من خلايا الدم البيضاء الخاصة بك. سيتم جمع خلايا الدم منك لتحضير دواؤك .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيأخذ طبيبك بعضًا من دمك باستخدام قسطرة (أنبوب) في الوريد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم فصل بعض خلايا الدم البيضاء عن دمك - ويعاد باقي الدم إلى الوريد. تسمى هذه العملية &quot;فصل كريات الدم البيضاء&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن تستغرق هذه العملية من 3 إلى 6 ساعات وقد تحتاج إلى التكرار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم إرسال خلايا الدم البيضاء الخاصة بك إلى مركز التصنيع حيث يتم تعديلها لتحضير كارفيكتي. هذه العملية تستغرق حوالى 4 أسابيع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أثناء تحضير كارفيكتي يمكن أن تحصل على أدوية أخرى لعلاج المايلوما المتعددة حتى لا يتطور إلى الأسوأ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية التي سيتم إعطاؤها قبل العلاج بكارفيكتي</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>خلال بضعة أيام&nbsp; قبل</strong> <strong>العلاج</strong><strong>- </strong>سيتم إعطاؤك ما يسمى &nbsp;&quot;بالعلاج المستنفذ للخلايا اللمفاوية&quot; لتحضير جسمك لتلقي كارفيكتي. يقلل هذا العلاج من عدد خلايا الدم البيضاء في الدم، بما يسمح لخلايا الدم البيضاء المعدلة وراثيًا في كارفيكتي بالتكاثر في الأعداد عند إعادتها إلى جسمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>خلال 30 إلى 60 دقيقة قبل العلاج </strong><strong>- </strong>يمكن أن يتم إعطاؤك أدوية أخرى. قد تشتمل هذه الأدوية على ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الهيستامين لردات الفعل التحسسية - مثل ديفينهيدرامين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية الحمى - مثل باراسيتامول.</p><p dir="RTL">سيتحقق طبيبك أو ممرضتك بعناية من أن علاج كارفيكتي الذي ستتلقاه محضر من خلايا الدم البيضاء الخاصة بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يتم إعطاؤك كارفيكتي</strong></p><p dir="RTL">كارفيكتي هو علاج لمرة واحدة. ولن يُعطى لك مرة أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيعطيك طبيبك أو ممرضتك كارفيكتي بالتنقيط في الوريد. وهذا ما يسمى &quot;التسريب في الوريد&quot; وعادة ما يكون أقل من 60 دقيقة.</p><p dir="RTL">كارفيكتي هو النسخة المعدلة وراثيًا من خلايا دمك البيضاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيتخذ اختصاصي الرعاية الصحية الذي سيعطيك كارفيكتي الاحتياطات المناسبة لمنع انتقال الأمراض المعدية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوف يتبع هذا الاختصاصي أيضًا الإرشادات المتفق عليها محليا لتنظيف أو التخلص من أي مادة ملامسة لدواء كارفيكتي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإجراءات الواجب اتخاذها بعد أن يتم إعطاؤك كارفيكتي</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خطط للبقاء بالقرب من المستشفى التي تلقيت فيها العلاج لمدة 4 أسابيع على الأقل بعد أن يتم إعطاؤك كارفيكتي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستحتاج إلى زيارة المستشفى كل يوم لمدة 14 يومًا على الأقل بعد أن يتم إعطاؤك كارفيكتي. هذا حتى يتمكن طبيبك من التحقق مما إذا كان كارفيكتي يعمل بشكل فعال ويعالجك إذا ظهرت عليك أي أعراض جانبية. إذا ظهرت عليك أعراض جانبية خطيرة، فقد تحتاج إلى البقاء في المستشفى حتى يتم علاج الأعراض الجانبية التي قد تظهر عليك وتتمكن بعد ذلك من مغادرة المستشفى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا فاتتك أي مواعيد، فاتصل بطبيبك أو بمركز العلاج في أقرب وقت ممكن لتحديد موعد جديد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيُطلب منك المشاركة في دراسة بحثية ستستمر لمدة 15 عامًا على الأقل وذلك لملاحظة صحتك و لفهم بشكل أفضل &nbsp;التأثيرات طويلة المدى لدواء كارفيكتي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنتيجة &nbsp;لتواجد خلايا كارفيكتي في دمك ، قد تشير بعض الاختبارات المعملية الخاصة بفيروس نقص المناعة البشرية (HIV) إلى نتيجة إيجابية &nbsp;بشكل غير صحيح على الرغم من أنها قد تكون سلبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتبرع بالدم أو الأعضاء أو الأنسجة أو الخلايا لعمليات الزرع بعد تلقيك لدواء كارفيكتي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء أعراضاً جانبية، على الرغم من عدم حدوثها للجميع.</p><p dir="RTL">يمكن أن يسبب كارفيكتي أعراضاً جانبية قد تكون خطيرة أو مهددة للحياة.</p><p dir="RTL"><strong>الأعراض الجانبية الخطيرة</strong></p><p dir="RTL">احصل على المساعدة الطبية مباشرة إذا كنت تعاني من أي من الأعراض الجانبية الخطيرة التالية والتي قد تكون شديدة ويمكن أن تكون قاتلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل مناعي خطير يعرف باسم متلازمة إفراز السيتوكين (CRS)، وتشتمل بعض الأعراض على:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض شائعة جدًا (</strong>قد تظهر لدى أكثر من 1 من كل 10 أشخاص):</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة، حمى (38 درجة مئوية أو أعلى)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات قلب سريعة وصعوبة في التنفس</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم الذي يمكن أن يجعلك تشعر بالدوار أو الدوخة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آثار على جهازك العصبي، والتي يمكن أن تحدث أعراضها بعد أيام أو أسابيع من تلقيك التنقيط ، وقد تكون غير ملحوظة في البداية. قد تكون بعض هذه الأعراض علامات لرد فعل مناعي خطير يسمى &quot;متلازمة السمية العصبية المرتبطة بالخلايا المناعية&quot; (ICANS) أو قد تكون علامات وأعراض لمرض باركنسون.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض شائعة جدًا</strong> (قد تظهر لدى أكثر من 1 من كل 10 أشخاص):</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالارتباك،</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الانتباه، تشوش، قلق، فقدان الذاكرة،</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في الكلام أو تلعثم،</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;بطء الحركة ، تغيرات في الكتابة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض شائعة </strong>&nbsp;(قد تظهر لدى ما يصل إلى شخص واحد من كل 10 أشخاص):</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان التناسق الحركي بما يؤثر على الحركة والتوازن،</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة القراءة والكتابة وفهم الكلمات،</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في الشخصية، والتي قد تشمل قلة الكلام وعدم الاهتمام بالأنشطة وانخفاض استخدام تعبيرات الوجه</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يزيد كارفيكتي من خطر العدوى التي تهدد الحياة والتي قد تؤدي إلى الوفاة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لاحظت أي من الأعراض الجانبية المذكورة أعلاه، فعليك الحصول على مساعدة طبية على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الأخرى</strong></p><p dir="RTL">الأعراض الجانبية الأخرى مذكورة أدناه. أخبر طبيبك أو ممرضتك إذا عانيت من أي من هذه الأعراض الجانبية.</p><p dir="RTL"><strong>أعراض شائعة جدًا (</strong>قد تؤثر على أكثر من 1 من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأنف أو الجيوب الأنفية أو الحلق (نزلة برد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى بكتيرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال وضيق التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي (عدوى الرئة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lrm;عدوى فيروسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم، بما في ذلك آلام العضلات والمفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم الناجم عن تراكم السوائل في الجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب الشديد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان (الشعور بالإعياء)، قلة الشهية، إمساك، قيء، إسهال</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>مشاكل في الحركة بما في ذلك التشنجات والتقلصات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الأعصاب الذي قد يسبب وخز أو تنميل أو ألم أو فقدان الإحساس بالألم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الأجسام المضادة التي تسمى &quot;الغلوبيولين المناعي&quot; في الدم، والذي قد يؤدي إلى الإصابة بالعدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الأكسجين في الدم مما يسبب صعوبة في التنفس وكحة و صداع و الارتباك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع في ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف ويمكن أن يكون شديدًا يسمى &quot;نزيف&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج فحص الدم غير الطبيعية التي تشير إلى: &nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء (يشمل العدلات والخلايا الليمفاوية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدموية (الخلايا التي تساعد الدم على التجلط)، وعدد خلايا الدم الحمراء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الكالسيوم والصوديوم والبوتاسيوم والمغنيسيوم والفوسفات في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى &quot;الألبومين&quot; وهو نوع من البروتين في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في تجلط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى بروتين &quot;الفيريتين&quot; في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى إنزيمات &quot;ناقلة الغاما -جلوتاميل &quot; و&quot;ناقلة الأمين &quot; في الدم</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض شائعة (</strong> قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردات فعل تحسسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء (العدلات)، التي تظهر في العدوى والحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة والأمعاء الفيروسي (التهاب المعدة والأمعاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة البلع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى المسالك البولية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الفطريات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع عدد أحد أنواع خلايا الدم البيضاء (الخلايا الليمفاوية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى شديدة في جميع أنحاء الجسم (تعفن الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل كلوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل مناعي خطير يشمل خلايا الدم و قد يؤدي إلى تضخم الكبد والطحال يسمى &quot;داء البلعمة&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة خطيرة حيث يتسرب السائل من الأوعية الدموية إلى أنسجة الجسم تسمى &quot;متلازمة تسرب الشعيرات الدموية&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل خطيرة ناجمة عن التحلل السريع للخلايا السرطانية (متلازمة انحلال الورم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات (التشنجات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات الإنزيمات في الدم تسمى &quot;الفوسفاتيز القلوية&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رعاش العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف خفيف في العضلات بسبب تلف في الأعصاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السقوط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك حاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنميل في الوجه وصعوبة في &nbsp;تحريك عضلات الوجه والعيون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رؤية مزدوجة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات سريعة في العين التي لا تستطيع التحكم بها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lrm;ارتفاع مستوى &quot;البيليروبين&quot; في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخثر الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجلطة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى بروتين&quot;سي التفاعلي&quot; في الدم بما قد يشير إلى وجود عدوى أو التهاب</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض غير شائعة</strong> (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص):</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالوخز والتنميل وألم في اليدين والرجلين وصعوبة في المشي وضعف في الذراع و/أوالساق وصعوبة في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع جديد من السرطان يبدأ في نوع من خلايا الدم البيضاء تسمى خلايا T (الورم الخبيث الثانوي من أصل خلايا T)</p><p dir="RTL">أخبر طبيبك أو ممرضتك إذا عانيت من أي من الأعراض الجانبية المذكورة أعلاه. لا تحاول معالجة أعراضك باستعمال أدوية أخرى بنفسك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تفاقمت أي من الأعراض الجانبية، أو إذا لاحظت أي أعراض جانبية غير مدرجة في هذه النشرة، يرجى إخبار طبيبك أو ممرضتك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المعلومات التالية مخصصة للطبيب فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على ملصق الحاوية وكيس الحقن بعد الحروف &quot;EXP&quot;</p><p dir="RTL">يتم تخزين هذا الدواء مجمدًا في النيتروجين السائل في درجة حرارة ( تقل عن أو تساوي-120 درجة مئوية) حتى تتم إذابته للاستخدام.</p><p dir="RTL">لا تقم بإعادة التجميد .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هي مكونات دواء</strong> <strong>كارفيكتي</strong></p><p dir="RTL">المادة الفعالة هي سيلتاكبتاجين أوتوليوسيل.</p><p dir="RTL">يحتوي كل كيس تنقيط كارفيكتي على سيلتاكبتاجين أوتوليوسيل خلية - محلول مشتت يحتوي على &nbsp;3.2&nbsp;&times;&nbsp;10<sup>6</sup>&nbsp;&ndash;&nbsp;1&nbsp;&times;&nbsp;10<sup>8</sup><strong>&nbsp;</strong>خلايا T CAR- إيجابي قابلة للنمو معلقة في محلول حفظ بالتبريد.يحتوي كيس التنقيط على 30 مل أو 70 مل من المحلول المشتت للتنقيط الوريدي.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">تشمل المكونات الأخرى محلول (Cryostor CS5) المستخدم لحفظ الخلايا المجمدة (راجع القسم 2، يحتوي كارفيكتي على ثنائي ميثيل السلفوكسيد (DMSO) وكاناميسين).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على خلايا بشرية معدلة وراثياً.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو</strong> <strong>كارفيكتي</strong> <strong>وما هي محتويات العبوة</strong></p><p dir="RTL">كارفيكتي هو محلول عديم اللون وقد يميل للون الأبيض، بما في ذلك ظلال من الأبيض والأصفر والوردي،30 مل أو 70 مل خلية مشتتة للتنقيط مزودة في كيس محاليل بحجم 50 مل أو 250 مل على التوالي، معبأ بشكل فردي داخل علبة مبرد الألمنيوم .</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق</strong></p><p dir="RTL">جانسن سيلاج انترناشونال ان فى</p><p dir="RTL">ترنهوتسويج- 30</p><p dir="RTL">بي-2340 بيرس</p><p dir="RTL">بلجيكا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">جانسن فارماسيوتيكالس، انك</p><p dir="RTL">1000 روت 202</p><p dir="RTL">ساوث راريتان، نيو جيرسي 08869</p><p dir="RTL">الولايات المتحدة الأمريكية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	للاتصال بنا، يرجى زيارة موقعنا على www.janssen.com/contact-us  
	
	تمت آخر مراجعة لهذه النشرة في يوليو 2024. 

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CARVYKTI 3.2 × 106 – 1 × 108 cells dispersion for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2.1 General description

CARVYKTI (ciltacabtagene autoleucel) is a genetically modified autologous cell-based product,
containing T cells transduced ex vivo using a replication incompetent lentiviral vector encoding an
anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR), comprising two single domain
antibodies linked to a 4-1BB costimulatory domain and a CD3-zeta signaling domain.

2.2 Qualitative and quantitative composition

Each patient-specific infusion bag of CARVYKTI contains ciltacabtagene autoleucel at a
batch-dependent concentration of autologous T cells genetically modified to express an anti-BCMA
chimeric antigen receptor (CAR-positive viable T cells) (see section 4.2). The medicinal product is
packaged in one infusion bag containing a cell dispersion for infusion of 3.2 × 106 to 1 × 108 CARpositive
viable T cells suspended in a cryopreservative solution.
An infusion bag contains 30 mL or 70 mL of dispersion for infusion.
The cellular composition and the final cell number is dependent on patient body weight and varies
between individual patient batches. In addition to T cells, Natural Killer (NK) cells may be present.
The quantitative information of the medicinal product including the total viable cell concentration,
volume of dispersion and total number of CAR+ cells per bag and supplied dose is presented in the Lot
Information Sheet included with the cryo cassette used for transport of CARVYKTI.
Excipient(s) with known effect
Each dose of CARVYKTI contains 0.05 mL of dimethyl sulfoxide (DMSO) per mL and residual
kanamycin (see section 4.4).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dispersion for infusion
A colourless to white, including shades of white, yellow, and pink, dispersion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>CARVYKTI is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>CARVYKTI must be administered in a qualified treatment centre.</p><p>Therapy should be initiated under the direction and supervision of a healthcare professional experienced in the treatment of haematological malignancies and trained for administration and management of patients treated with CARVYKTI.</p><p>Prior to infusion, the qualified treatment centre must have at least 1&nbsp;dose of tocilizumab available for use in the event of cytokine release syndrome (CRS), with access to an additional dose within 8&nbsp;hours of each previous dose (see section&nbsp;4.4). In the exceptional case where tocilizumab is not available due to a shortage that is listed in the European Medicines Agency shortage catalogue, suitable alternative measures to treat CRS instead of tocilizumab must be available prior to infusion.</p><p>Emergency equipment must be available prior to infusion and during the recovery period.</p><p><u>&nbsp;</u></p><p><u>Posology</u></p><p>&nbsp;</p><p>CARVYKTI is intended for autologous use (see section 4.4).</p><p>&nbsp;</p><p>Treatment consists of a single dose for infusion containing a dispersion of CAR-positive viable T&nbsp;cells in one infusion bag.</p><p>The target dose is 0.75&nbsp;x&nbsp;10<sup>6</sup>&nbsp;CAR-positive viable T cells/kg of body weight (not exceeding 1&nbsp;&times;&nbsp;10<sup>8</sup>&nbsp;CAR-positive viable T cells).</p><p>&nbsp;</p><p>Patients 100&nbsp;kg and below: 0.5&nbsp;-&nbsp;1&nbsp;x&nbsp;10<sup>6</sup>&nbsp;CAR-positive viable T cells/kg body weight.</p><p>Patients above 100&nbsp;kg: 0.5&nbsp;-&nbsp;1&nbsp;x&nbsp;10<sup>8</sup>&nbsp;CAR-positive viable T cells (non-weight based).</p><p>&nbsp;</p><p>See the accompanying Lot information sheet (LIS) for additional information pertaining to dose.</p><p>&nbsp;</p><p><em>Bridging therapy</em></p><p>Consider bridging therapy according to prescriber&rsquo;s choice prior to infusion with CARVYKTI to reduce tumour burden or stabilise the disease (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Pre-treatment (lymphodepleting regimen)</em></p><p>Lymphodepleting regimen must be delayed if a patient has serious adverse reactions from preceding bridging therapies (including clinically significant active infection, cardiac toxicity, and pulmonary toxicity) (see section&nbsp;5.1).</p><p>The availability of CARVYKTI should be confirmed prior to starting the lymphodepleting regimen.</p><p>A lymphodepleting regimen of cyclophosphamide 300&nbsp;mg/m<sup>2</sup> intravenous and fludarabine 30&nbsp;mg/m<sup>2</sup> intravenous should be administered daily for 3&nbsp;days. CARVYKTI infusion should be administered 5 to 7&nbsp;days after the start of the lymphodepleting regimen. If resolution of toxicities due to the lymphodepleting regimen to Grade 1 or lower takes more than 14&nbsp;days, thereby resulting in delays to CARVYKTI dosing, the lymphodepleting regimen should be re-administered after a minimum of 21&nbsp;days following the first dose of the first lymphodepleting regimen.</p><p>For dose modifications of cyclophosphamide and fludarabine, see corresponding Summaries of Product Characteristics of cyclophosphamide and fludarabine.</p><p>&nbsp;</p><p><em>Premedication</em></p><p>The following pre-infusion medications should be administered to all patients 30&nbsp;to 60&nbsp;minutes prior to CARVYKTI infusion:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antipyretic (oral or intravenous paracetamol 650 to 1,000&nbsp;mg).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antihistamine (oral or intravenous diphenhydramine 25 to 50&nbsp;mg or equivalent).</p><p>&nbsp;</p><p>The use of prophylactic systemic corticosteroids should be avoided as it may interfere with the activity of CARVYKTI.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Elderly</em></p><p>No dose adjustment is required in patients &ge;&nbsp;65&nbsp;years of age.</p><p>&nbsp;</p><p><em>Patients seropositive for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)</em></p><p>There is currently no experience with manufacturing CARVYKTI for patients testing positive for HIV, active HBV, or active HCV. Screening for HBV, HCV and HIV and other infectious agents must be performed before collection of cells for manufacturing.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of CARVYKTI in children aged below 18&nbsp;years of age have not been established.</p><p>No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>CARVYKTI is for intravenous use only.</p><p>&nbsp;</p><p>Do NOT use a leukodepleting filter.</p><p><em>&nbsp;</em></p><p><em>Preparation of </em><em>CARVYKTI for infusion</em></p><p>Prior to infusion and during the recovery period, the availability of tocilizumab, or suitable alternatives, in the exceptional case where tocilizumab is not available due to a shortage that is listed in the European Medicines Agency shortage catalogue, and emergency equipment must be ensured.</p><p>&nbsp;</p><p>Before infusion, it must be confirmed that the patient&rsquo;s identity matches the unique patient information on the CARVYKTI cryo cassette, infusion bag and on the Lot Information Sheet. (see section&nbsp;4.4).</p><p>&nbsp;</p><p>The medicinal product must not be thawed until it is ready to be used. The timing of CARVYKTI thaw and infusion should be coordinated; the infusion time should be confirmed in advance, and the start time for thaw must be adjusted so that CARVYKTI is available for infusion when the patient is ready. The medicinal product should be administered immediately after thawing and the infusion should be completed within 2.5&nbsp;hours of thawing.</p><p><em>&nbsp;</em></p><p>For detailed instructions on preparation, administration, measures to take in case of accidental exposure and disposal of CARVYKTI, see section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
Contraindications of the lymphodepleting chemotherapy and supportive therapy should be considered.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>The traceability requirements of cell-based advanced therapy medicinal products must apply. To ensure traceability, the name of the medicinal product, the batch number and the name of the treated patient should be kept for a period of 30&nbsp;years after the expiry date of the medicinal product<em>.</em></p><p><em>&nbsp;</em></p><p><u>General</u></p><p><em>Autologous use</em></p><p>CARVYKTI is intended solely for autologous use and must not, under any circumstances, be administered to other patients. CARVYKTI must not be infused if the information on the product labels and Lot Information Sheet does not match the patient&rsquo;s identity.</p><p>&nbsp;</p><p><em>Clinical assessment prior to CARVYKTI infusion</em></p><p>CARVYKTI infusion should be delayed if a patient has any of the following conditions:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clinically significant active infection or inflammatory disorders,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; grade &ge;&nbsp;3 non-haematologic toxicities of cyclophosphamide and fludarabine lymphodepletion regimen, except for Grade&nbsp;3&nbsp;nausea, vomiting, diarrhoea, or constipation. CARVYKTI infusion should be delayed until resolution of these events to Grade &le;&nbsp;1,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; active graft versus host disease.</p><p>&nbsp;</p><p>Patients with active or prior history of significant central nervous system (CNS) disease or inadequate renal, hepatic, pulmonary, or cardiac function are likely to be more vulnerable to the consequences of the adverse reactions described below and require special attention. There is no experience of use of CARVYKTI in patients with CNS involvement of myeloma or other pre-existing, clinically relevant CNS illnesses.</p><p>The efficacy/safety of CARVYKTI in patients previously exposed to other anti-BCMA treatments is unknown.</p><p>There is limited evidence available on efficacy/safety of CARVYKTI in re-treated patients.</p><p>&nbsp;</p><p><em>Rapidly progressing disease</em></p><p>When considering patients for CARVYKTI treatment, physicians should assess the impact of rapidly progressing disease on the ability of patients to receive CAR-T infusion. Some patients may not benefit from CARVYKTI treatment due to potential increased risk of early death if disease progresses rapidly during bridging therapy.</p><p>&nbsp;</p><p><em>Monitoring after infusion</em></p><p>Patients should be monitored daily for 14&nbsp;days after the CARVYKTI infusion at a qualified clinical facility, and then periodically for an additional 2&nbsp;weeks after CARVYKTI infusion, for signs and symptoms of CRS, neurologic events and other toxicities (see section&nbsp;4.4).</p><p>Patients should be instructed to remain within proximity of a qualified clinical facility for at least 4&nbsp;weeks following infusion.</p><p>&nbsp;</p><p><u>Cytokine release syndrome</u></p><p>Cytokine release syndrome, including fatal or life-threatening reactions, can occur after CARVYKTI infusion.</p><p>&nbsp;</p><p>Nearly all patients experienced CRS after CARVYKTI infusion, with majority of these being Grade&nbsp;1 or Grade&nbsp;2 <em>(</em>see section&nbsp;4.8<em>)</em>. The median time from CARVYKTI infusion (Day 1) to onset of CRS was 7&nbsp;days (range: 1 to 23&nbsp;days). Approximately 83% of patients experienced CRS onset after Day&nbsp;3 of receiving the CARVYKTI infusion.</p><p>&nbsp;</p><p>In almost all cases, duration of CRS ranged from 1 to 18&nbsp;days (median duration, 4&nbsp;days). Eighty‑nine&nbsp;percent of patients had a CRS duration of &le;&nbsp;7&nbsp;days.</p><p><em>&nbsp;</em></p><p>Clinical signs and symptoms of CRS may include, but are not limited to, fever (with or without rigors), chills, hypotension, hypoxia and elevated liver enzymes. Potentially life-threatening complications of CRS may include cardiac dysfunction, neurologic toxicity and haemophagocytic lymphohistiocytosis (HLH). Patients who develop HLH may have an increased risk of severe bleeding. Patients should be closely monitored for signs or symptoms of these events, including fever.<em> </em>Risk factors for severe CRS include high pre‑infusion tumour burden, active infection and early onset of fever or persistent fever after 24&nbsp;hours of symptomatic treatment.</p><p>&nbsp;</p><p>The infusion of CARVYKTI should be delayed if the patient has unresolved serious adverse reactions from preceding lymphodepleting or bridging therapies (including cardiac toxicity and pulmonary toxicity), rapid disease progression and clinically significant active infection&nbsp;(see<em> </em>section&nbsp;4.2). Appropriate prophylactic and therapeutic treatment for infections should be provided, and complete resolution of any active infections should be ensured prior to CARVYKTI infusion. Infections may also occur concurrently with CRS and may increase the risk of a fatal event.</p><p>&nbsp;</p><p>The availability of at least one dose of tocilizumab for use in the event of CRS should be ensured prior to infusion. The qualified treatment centre must have access to an additional dose of tocilizumab within 8&nbsp;hours of each previous dose. In the exceptional case where tocilizumab is not available due to a shortage that is listed in the European Medicines Agency shortage catalogue, the treatment centre must have access to suitable alternative measures instead of tocilizumab to treat CRS. Patients should be monitored for signs and symptoms of CRS daily for 14&nbsp;days after the CARVYKTI infusion at a qualified clinical facility, and then periodically for an additional two weeks after CARVYKTI infusion.</p><p>&nbsp;</p><p>Patients should be counselled to seek immediate medical attention should signs or symptoms of CRS occur at any time. At the first sign of CRS, the patient should be immediately evaluated for hospitalisation and treatment with supportive care, tocilizumab, or tocilizumab and corticosteroids should be instituted as indicated in Table 1 below.</p><p>&nbsp;</p><p>Evaluation for HLH should be considered in patients with severe or unresponsive CRS. For patients with high pre-infusion tumour burden, early onset of fever, or persistent fever after 24&nbsp;hours, early tocilizumab should be considered. The use of myeloid growth factors, particularly granulocyte macrophage-colony stimulating factor (GM-CSF), should be avoided during CRS. Consider reducing baseline burden of disease with bridging therapy prior to infusion with CARVYKTI in patients with high tumour burden (see section&nbsp;4.2).</p><p>&nbsp;</p><p><em>Management of cytokine release syndrome associated with CARVYKTI</em></p><p>If CRS is suspected, manage according to the recommendations in Table 1. Supportive care for CRS (including but not limited to anti-pyretic agents, IV fluid support, vasopressors, supplemental oxygen, etc.) should be administered as appropriate. Laboratory testing to monitor for disseminated intravascular coagulation (DIC), haematology parameters, as well as pulmonary, cardiac, renal, and hepatic function should be considered. Other monoclonal antibodies targeting cytokines (for example, anti-IL1 and/or anti-TNF&alpha;), or therapy directed at reduction and elimination of CAR-T cells, may be considered for patients who develop high grade CRS and HLH that remain severe or life-threatening following prior administration of tocilizumab and corticosteroids.</p><p>&nbsp;</p><p>If concurrent neurologic toxicity is suspected during CRS, administer:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corticosteroids according to the more aggressive intervention based on the CRS and neurologic toxicity grades in Tables&nbsp;1 and 2,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tocilizumab according to the CRS grade in Table&nbsp;1,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anti-seizure medication according to the neurologic toxicity in Table&nbsp;2.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:638px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;1:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CRS grading and management guidance</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>CRS Grade<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Tocilizumab<sup>b</sup></strong></p></td><td style="vertical-align:top"><p><strong>Corticosteroids<sup>f</sup></strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 1 </strong></p><p>Temperature &ge;38&nbsp;&deg;C<sup>c</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Tocilizumab 8&nbsp;mg/kg intravenously (IV) over 1&nbsp;hour (not to exceed 800&nbsp;mg) may be considered.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>N/A</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Grade 2 </strong></p><p>Symptoms require and respond to moderate intervention.</p><p><strong>&nbsp;</strong></p><p>Temperature &ge;38&nbsp;&deg;C<sup>c</sup> with:</p><p><strong>&nbsp;</strong></p><p>Hypotension not requiring vasopressors,</p><p>and/or,</p><p><strong>&nbsp;</strong></p><p>Hypoxia requiring oxygen via cannula<sup>e</sup> or blow-by,</p><p><strong>&nbsp;</strong></p><p>or,</p><p><strong>&nbsp;</strong></p><p>Grade 2 organ toxicity.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Administer tocilizumab 8&nbsp;mg/kg IV over 1 hour (not to exceed 800&nbsp;mg).</p><p><strong>&nbsp;</strong></p><p>Repeat tocilizumab every 8&nbsp;hours as needed if not responsive to intravenous fluids up to 1&nbsp;litre or increasing supplemental oxygen.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Consider methylprednisolone 1&nbsp;mg/kg intravenously (IV) twice daily or dexamethasone (e.g., 10&nbsp;mg IV every 6&nbsp;hours).</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>If no improvement within 24&nbsp;hours or rapid progression, repeat tocilizumab and escalate dose of dexamethasone (20&nbsp;mg IV every 6&nbsp;to 12&nbsp;hours).</p><p><strong>&nbsp;</strong></p><p>After 2&nbsp;doses of tocilizumab, consider alternative anti-cytokine agents.<sup>d</sup></p><p><strong>&nbsp;</strong></p><p>Do not exceed 3&nbsp;doses of tocilizumab in 24&nbsp;hours, or 4&nbsp;doses in total.</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Grade 3 </strong></p><p>Symptoms require and respond to aggressive intervention.</p><p><strong>&nbsp;</strong></p><p>Temperature &ge;38&nbsp;&deg;C<sup>c</sup> with:</p><p><strong>&nbsp;</strong></p><p>Hypotension requiring one vasopressor with or without vasopressin,</p><p>and/or,</p><p><strong>&nbsp;</strong></p><p>Hypoxia requiring oxygen via high-flow nasal cannula<sup>e</sup>, facemask, non-rebreather mask, or Venturi mask,</p><p><strong>&nbsp;</strong></p><p>or,</p><p><strong>&nbsp;</strong></p><p>Grade 3 organ toxicity or Grade 4 transaminitis.</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Per Grade 2</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Administer methylprednisolone 1&nbsp;mg/kg IV twice daily or dexamethasone (e.g., 10&nbsp;mg IV every 6&nbsp;hours).</p><p><strong>&nbsp;</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>If no improvement within 24&nbsp;hours or rapid progression, repeat tocilizumab and escalate dose of dexamethasone (20&nbsp;mg IV every 6&nbsp;to 12&nbsp;hours).</p><p><strong>&nbsp;</strong></p><p>If no improvement within 24&nbsp;hours or continued rapid progression, switch to methylprednisolone 2&nbsp;mg/kg IV every 12&nbsp;hours.</p><p><strong>&nbsp;</strong></p><p>After 2&nbsp;doses of tocilizumab, consider alternative anti-cytokine agents.<sup>d</sup></p><p><strong>&nbsp;</strong></p><p>Do not exceed 3&nbsp;doses of tocilizumab in 24&nbsp;hours, or 4&nbsp;doses in total.</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Grade 4 </strong></p><p>Life-threatening symptoms.</p><p>Requirements for ventilator support, continuous veno-venous haemodialysis (CVVHD).</p><p><strong>&nbsp;</strong></p><p>Temperature &ge;38&nbsp;&deg;C<sup>c</sup> with:</p><p><strong>&nbsp;</strong></p><p>Hypotension requiring multiple vasopressors (excluding vasopressin),</p><p>and/or,</p><p><strong>&nbsp;</strong></p><p>Hypoxia requiring positive pressure (e.g., CPAP, BiPAP, intubation, and mechanical ventilation),</p><p><strong>&nbsp;</strong></p><p>or,</p><p><strong>&nbsp;</strong></p><p>Grade 4 organ toxicity (excluding transaminitis).</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Per Grade 2</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Administer dexamethasone 20&nbsp;mg IV every 6&nbsp;hours.</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>After 2&nbsp;doses of tocilizumab, consider alternative anti-cytokine agents<sup>d</sup>. Do not exceed 3&nbsp;doses of tocilizumab in 24&nbsp;hours, or 4&nbsp;doses in total.</p><p><strong>&nbsp;</strong></p><p>If no improvement within 24&nbsp;hours, consider methylprednisolone (1-2&nbsp;g IV, repeat every 24&nbsp;hours if needed; taper as clinically indicated) or other immunosuppressants (e.g., other anti-T cell therapies).</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp; Based on ASTCT 2019 grading system (Lee et.al, 2019), modified to include organ toxicity.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp; Refer to tocilizumab prescribing information for details. Consider alternative measures (see Sections&nbsp;4.2. and 4.4).</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp; Attributed to CRS. Fever may not always be present concurrently with hypotension or hypoxia, as it may be masked by interventions such as antipyretics or anti-cytokine therapy (e.g., tocilizumab or steroids). Absence of fever does not impact CRS management decision. In this case, CRS management is driven by hypotension and/or hypoxia and by the more severe symptom not attributable to any other cause.</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp;&nbsp; Monoclonal antibodies targeting cytokines (for example, anti-IL1 such as anakinra) may be considered based on institutional practice for unresponsive CRS.</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp;&nbsp; Low-flow nasal cannula is &le;6&nbsp;L/min; high-flow nasal cannula is &gt;6&nbsp;L/min.</p><p><sup>f</sup>&nbsp;&nbsp;&nbsp;&nbsp; Continue corticosteroids use until the event is Grade 1 or less; taper steroids if total corticosteroid exposure is greater than 3&nbsp;days.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Neurologic toxicities</u></p><p>Neurologic toxicities occur frequently following treatment with CARVYKTI and can be fatal or life‑threatening (see section&nbsp;4.8). Neurologic toxicities included ICANS, movement and neurocognitive toxicity (MNT) with signs and symptoms of parkinsonism, Guillain-Barr&eacute; syndrome, peripheral neuropathies and cranial nerve palsies. Patients should be counselled on the signs and symptoms of these neurologic toxicities, and on the delayed nature of onset of some of these toxicities. Patients should be instructed to seek immediate medical attention for further assessment and management if signs or symptoms of any of these neurologic toxicities occur at any time.</p><p>&nbsp;</p><p><em>Immune effector cell-associated neurotoxicity syndrome (ICANS)</em></p><p>Patients receiving CARVYKTI may experience fatal or life-threatening ICANS following treatment with CARVYKTI, including before CRS onset, concurrent with CRS, following resolution of CRS or in the absence of CRS. Symptoms included aphasia, slow speech, dysgraphia, encephalopathy, depressed level of consciousness and confusional state.</p><p>&nbsp;</p><p>Reduction of baseline burden of disease with bridging therapy prior to infusion with CARVYKTI in patients with high tumour burden should be considered, which may mitigate the risk of developing neurologic toxicity (see section&nbsp;4.8). Patients should be monitored for signs or symptoms of ICANS for four weeks after infusion. At the first sign of ICANS, the patient should be immediately evaluated for hospitalisation and treatment instituted with supportive care as indicated in Table&nbsp;2 below. Early detection and aggressive treatment of CRS or ICANS may be important to prevent neurologic toxicity from occurring or worsening. Continue to monitor patients for signs and symptoms of neurologic toxicities after recovery from CRS and/or ICANS.</p><p>&nbsp;</p><p><em><u>Management of neurologic toxicity associated with CARVYKTI</u></em></p><p>At the first sign of neurologic toxicity including ICANS, neurology evaluation should be considered. Rule out other causes of neurologic symptoms. Provide intensive care and supportive therapy for severe or life-threatening neurologic toxicities.</p><p>&nbsp;</p><p>If concurrent CRS is suspected during the neurologic toxicity event, administer:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corticosteroids according to the more aggressive intervention based on the CRS and neurologic toxicity grades in Tables&nbsp;1 and 2,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tocilizumab according to CRS grade in Table&nbsp;1,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anti-seizure medication according to neurologic toxicity in Table&nbsp;2.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:101%"><thead><tr><td colspan="2" style="vertical-align:top"><p><strong>Table&nbsp;2:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Guideline for management of ICANS</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>ICANS Grade<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Corticosteroids</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 1</strong></p><p>&nbsp;</p><p>ICE score 7-9<sup>b</sup></p><p>&nbsp;</p><p>or depressed level of consciousness: awakens spontaneously.</p></td><td style="vertical-align:top"><p>Consider dexamethasone<sup>c</sup> 10&nbsp;mg intravenously every 6&nbsp;to 12&nbsp;hours for 2&nbsp;to 3&nbsp;days.</p><p>&nbsp;</p><p>Consider non-sedating, anti-seizure medicines (e.g., levetiracetam) for seizure prophylaxis.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 2</strong></p><p>&nbsp;</p><p>ICE score-3-6<sup>b</sup></p><p>&nbsp;</p><p>or depressed level of consciousness: awakens to voice</p></td><td style="vertical-align:top"><p>Administer dexamethasone<sup>c</sup> 10&nbsp;mg intravenously every 6&nbsp;hours for 2-3&nbsp;days, or longer for persistent symptoms.</p><p>&nbsp;</p><p>Consider steroid taper if total corticosteroid exposure is greater than 3&nbsp;days.</p><p>&nbsp;</p><p>Consider non-sedating, anti-seizure medicines (e.g., levetiracetam) for seizure prophylaxis.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 3</strong></p><p>&nbsp;</p><p>ICE score-0-2<sup>b</sup></p><p>(If ICE score is 0, but the patient is arousable (e.g., awake with global aphasia) and able to perform assessment)</p><p>&nbsp;</p><p>or depressed level of consciousness: awakens only to tactile stimulus,</p><p>&nbsp;</p><p>or seizures, either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any clinical seizure, focal or generalised, that resolves rapidly, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-convulsive seizures on EEG that resolve with intervention,</p><p>&nbsp;</p><p>or raised intracranial pressure (ICP): focal/local oedema on neuroimaging<sup>d</sup>.</p></td><td style="vertical-align:top"><p>Administer dexamethasone<sup>c </sup>10&nbsp;mg-20&nbsp;mg intravenously every 6&nbsp;hours.</p><p>&nbsp;</p><p>If no improvement after 48&nbsp;hours or worsening of neurologic toxicity, escalate dexamethasone<sup>c</sup> dose to at least 20&nbsp;mg intravenously every 6&nbsp;hours; taper within 7&nbsp;days,</p><p>&nbsp;</p><p>OR escalate to high-dose methylprednisolone (1&nbsp;g/day, repeat every 24&nbsp;hours if needed; taper as clinically indicated).</p><p>&nbsp;</p><p>Consider non-sedating, anti-seizure medicines (e.g., levetiracetam) for seizure prophylaxis.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 4</strong></p><p>&nbsp;</p><p>ICE score-0<sup>b</sup> (Patient is unarousable and unable to perform ICE assessment)</p><p>&nbsp;</p><p>or depressed level of consciousness either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patient is unarousable or requires vigorous or repetitive tactile stimuli to arouse, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stupor or coma,</p><p>&nbsp;</p><p>or seizures, either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; life-threatening prolonged seizure (&gt;5&nbsp;min), or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; repetitive clinical or electrical seizures without return to baseline in between,</p><p>&nbsp;</p><p>or motor findings<sup>e</sup>:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; deep focal motor weakness such as hemiparesis or paraparesis,</p><p>&nbsp;</p><p>or raised ICP / cerebral oedema, with signs/symptoms such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diffuse cerebral oedema on neuroimaging, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decerebrate or decorticate posturing, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cranial nerve VI palsy, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; papilledema, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cushing&rsquo;s triad</p></td><td style="vertical-align:top"><p>Administer dexamethasone<sup>c</sup> 10&nbsp;mg-20&nbsp;mg intravenously every 6&nbsp;hours.</p><p>&nbsp;</p><p>If no improvement after 24&nbsp;hours or worsening of neurologic toxicity, escalate to high-dose methylprednisolone (1-2&nbsp;g/day, repeated every 24&nbsp;hours if needed; taper as clinically indicated).</p><p>&nbsp;</p><p>Consider non-sedating, anti-seizure medicines (e.g., levetiracetam) for seizure prophylaxis.</p><p>&nbsp;</p><p>If raised ICP/cerebral oedema is suspected, consider hyperventilation and hyperosmolar therapy. Give high-dose methylprednisolone (1-2&nbsp;g/day, repeat every 24&nbsp;hours if needed; taper as clinically indicated), and consider neurology and/or neurosurgery consultation.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>EEG=Electroencephalogram; ICE=Immune Effector Cell-Associated Encephalopathy</p><p>Note: &nbsp;&nbsp; ICANS grade and management is determined by the most severe event (ICE score, level of consciousness, seizure, motor findings, raised ICP/cerebral oedema), not attributable to any other cause.</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; ASTCT 2019 criteria for grading Neurologic Toxicity (Lee et.al, 2019).</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp; If patient is arousable and able to perform Immune Effector Cell-associated Encephalopathy (ICE) Assessment, assess as in Table 3 below.</p><p><sup>c</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>All references to dexamethasone administration are dexamethasone or equivalent.</p><p><sup>d</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Intracranial haemorrhage with or without associated oedema is not considered a neurotoxicity feature and is excluded from ICANS grading. It may be graded according to CTCAE v5.0.</p><p><sup>e</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Tremors and myoclonus associated with immune effector cell therapies may be graded according to CTCAE v5.0, but they do not influence ICANS grading.</p></td></tr></thead></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Table&nbsp;3: Immune Effector Cell-Associated Encephalopathy (ICE) assessment</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune Effector Cell-Associated Encephalopathy (ICE) Tool<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Points</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Orientation: </strong>Orientation to year, month, city, hospital</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p><strong>Naming: </strong>Name 3 objects (e.g., point to clock, pen, button)</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p><strong>Following commands: </strong>(e.g., &lsquo;Show me 2&nbsp;fingers&rsquo; or &lsquo;Close your eyes and stick out your tongue&rsquo;)</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Writing: </strong>Ability to write a standard sentence</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Attention: </strong>Count backwards from 100 by ten</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; ICE-Tool Scoring:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Score&nbsp;10: No impairment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Score&nbsp;7-9: Grade&nbsp;1 ICANS</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Score&nbsp;3-6: Grade&nbsp;2 ICANS</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Score&nbsp;0-2: Grade&nbsp;3 ICANS</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Score&nbsp;0: patient unarousable and unable to perform ICE assessment: Grade&nbsp;4 ICANS</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Movement and neurocognitive toxicity with signs and symptoms of parkinsonism</em></p><p>Neurologic toxicity of movement and neurocognitive toxicity with signs and symptoms of parkinsonism has been reported in trials of CARVYKTI. A cluster of symptoms with variable onset spanning more than one symptom domain was observed, including movement (e.g., micrographia, tremor, bradykinesia, rigidity, stooped posture, shuffling gait), cognitive (e.g., memory loss, disturbance in attention, confusion), and personality change (e.g., reduced facial expression, flat affect, masked facies, apathy), often with subtle onset (e.g., micrographia, flat affect), that in some patients progressed to an inability to work or care for oneself. Most of these patients presented a combination of two or more factors such as high tumour burden at baseline (bone marrow plasma cell &ge;80% or serum M-spike &ge;&nbsp;5&nbsp;g/dL or serum free light chain &ge;&nbsp;5,000&nbsp;mg/L), prior Grade&nbsp;2 or higher CRS, prior ICANS, and high CAR-T cell expansion and persistence. Treatment with levodopa/carbidopa (n=4), was not effective in improving symptomatology in these patients.</p><p>&nbsp;</p><p>Patients should be monitored for signs and symptoms of parkinsonism that may be delayed in onset and managed with supportive care measures.</p><p>&nbsp;</p><p><em>Guillain-Barr&eacute; syndrome</em></p><p>Guillain-Barr&eacute; syndrome (GBS) has been reported after treatment with CARVYKTI. Symptoms reported include those consistent with Miller-Fisher variant of GBS, motor weakness, speech disturbances, and polyradiculoneuritis (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Patients should be monitored for GBS. Patients presenting with peripheral neuropathy should be evaluated for GBS. Treatment with intravenous immunoglobulin (IVIG) and escalation to plasmapheresis should be considered, depending on toxicity severity.</p><p>&nbsp;</p><p><em>Peripheral neuropathy</em></p><p>Occurrence of peripheral neuropathy, including sensory, motor, or sensorimotor, have been reported in trials of CARVYKTI.</p><p>&nbsp;</p><p>Patients should be monitored for signs and symptoms of peripheral neuropathies. Management with short-course systemic corticosteroids should be considered, depending on the severity and progression of signs and symptoms.</p><p>&nbsp;</p><p><em>Cranial nerve palsies</em></p><p>Occurrence of 7<sup>th</sup>, 3<sup>rd</sup>, 5<sup>th</sup>, and 6<sup>th</sup> cranial nerve palsy, some of which were bilateral, worsening of cranial nerve palsy after improvement, and occurrence of peripheral neuropathy in patients with cranial nerve palsy have been reported in trials of CARVYKTI.</p><p>&nbsp;</p><p>Patients should be monitored for signs and symptoms of cranial nerve palsies. Management with short-course systemic corticosteroids should be considered, depending on the severity and progression of signs and symptoms.</p><p><u>&nbsp;</u></p><p><u>Prolonged and recurrent cytopenias</u></p><p>Patients may exhibit cytopenias for several weeks following lymphodepleting chemotherapy and CARVYKTI infusion and should be managed according to local guidelines. In trials of CARVYKTI, nearly all patients had one or more Grade&nbsp;3 or 4&nbsp;cytopenic adverse reactions. Most patients had a median time from infusion to first onset of Grade&nbsp;3 or 4&nbsp;cytopenia of less than two weeks with the majority of patients recovering to Grade&nbsp;2 or lower by Day&nbsp;30 (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Blood counts should be monitored prior to and after CARVYKTI infusion. For thrombocytopenia, supportive care with transfusions should be considered. Prolonged neutropenia has been associated with increased risk of infection. Myeloid growth factors, particularly GM-CSF, have the potential to worsen CRS symptoms and are not recommended during the first 3&nbsp;weeks after CARVYKTI or until CRS has resolved.</p><p>&nbsp;</p><p><u>Serious infections and febrile neutropenia</u></p><p>Serious infections, including life-threatening or fatal infections, occurred in patients after CARVYKTI infusion (see section&nbsp;4.8).</p><p>Patients should be monitored for signs and symptoms of infection prior to and during treatment with CARVYKTI and treated appropriately. Prophylactic antimicrobials should be administered according to local guidelines. Infections are known to complicate the course and management of concurrent CRS. Patients with clinically significant active infection should not start CARVYKTI treatment until the infection is controlled.</p><p>&nbsp;</p><p>In the event of febrile neutropenia, infection should be evaluated and managed appropriately with broad‑spectrum antibiotics, fluids and other supportive care, as medically indicated.</p><p>&nbsp;</p><p>Patients treated with CARVYKTI may be at an increased risk of severe/fatal COVID-19 infections. Patients should be counselled on the importance of prevention measures.</p><p><u>&nbsp;</u></p><p><u>Viral reactivation</u></p><p>HBV reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, can occur in patients treated with medicinal products directed against B cells.</p><p>&nbsp;</p><p>There is currently no experience with manufacturing CARVYKTI for patients testing positive for HIV, active HBV, or active HCV. Screening for HBV, HCV and HIV and other infectious agents must be performed before collection of cells for manufacturing (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Hypogammaglobulinaemia</u></p><p>Hypogammaglobulinaemia may occur in patients receiving CARVYKTI.</p><p>&nbsp;</p><p>Immunoglobulin levels should be monitored after treatment with CARVYKTI; IVIG should be administered for IgG &lt;400&nbsp;mg/dL. Manage according to standard guidelines, including antibiotic or antiviral prophylaxis and monitoring for infection.</p><p>&nbsp;</p><p><u>Secondary malignancies including of T-cell origin</u></p><p>Patients treated with CARVYKTI may develop secondary malignancies. T‑cell malignancies have been reported following treatment of haematological malignancies with a BCMA- or CD19- directed CAR T-cell therapy, including CARVYKTI. T-cell malignancies, including CAR-positive malignancies, have been reported within weeks and up to several years following administration of a CD19- or BMCA-, directed CAR T-cell therapy. There have been fatal outcomes.</p><p>&nbsp;</p><p>Patients should be monitored life-long for secondary malignancies. In the event a secondary malignancy occurs, the company should be contacted to obtain instructions on patient samples to collect for testing.</p><p>&nbsp;</p><p><u>Interference with virological testing</u></p><p>Due to limited and short spans of identical genetic information between the lentiviral vector used to create CARVYKTI and HIV, some HIV nucleic acid tests (NAT) may give a false positive result.</p><p>&nbsp;</p><p><u>Blood, organ, tissue and cell donation</u></p><p>Patients treated with CARVYKTI should not donate blood, organs, tissues and cells for transplantation. This information is provided in the Patient Alert Card which should be given to the patient.</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>Allergic reactions may occur with infusion of CARVYKTI. Serious hypersensitivity reactions, including anaphylaxis, may occur due to the dimethyl sulfoxide (DMSO) or residual kanamycin in CARVYKTI. Patients should be carefully monitored for 2&nbsp;hours after infusion for signs and symptoms of severe reaction. Treat promptly and manage patients appropriately according to the severity of the hypersensitivity reaction.</p><p>&nbsp;</p><p><u>Long-term follow-up</u></p><p>Patients are expected to enroll and be followed in a registry in order to better understand the long-term safety and efficacy of CARVYKTI.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No pharmacokinetic or pharmacodynamic drug interaction studies have been performed with CARVYKTI.</p><p>&nbsp;</p><p>The co-administration of agents known to inhibit T cell function has not been formally studied. The co-administration of agents known to stimulate T cell function has not been investigated and the effects are unknown.</p><p>&nbsp;</p><p>Some patients in the clinical trials on CARVYKTI required tocilizumab, corticosteroids and anakinra for management of CRS. CARVYKTI continues to expand and persist following tocilizumab administration. In Study MMY2001, patients treated with tocilizumab (n=68) had 81% and 72% higher CARVYKTI C<sub>max</sub> and AUC<sub>0-28d</sub>, respectively, as compared to patients (n=29) who did not receive tocilizumab. Patients who received corticosteroids (n=28) had 75% and 112% higher C<sub>max</sub> and AUC<sub>0-28d</sub>, respectively, compared with patients who did not receive corticosteroids (n=69). In addition, patients who received anakinra (n=20) had 41% and 72% higher C<sub>max</sub> and AUC<sub>0-28d,</sub> respectively, compared with patients who did not receive anakinra (n=77). In Study MMY3002, the results related to tocilizumab and corticosteroid were consistent with Study MMY2001.</p><p>&nbsp;</p><p><u>Live vaccines</u></p><p>The safety of immunisation with live viral vaccines during or following CARVYKTI treatment has not been studied. As a precautionary measure, vaccination with live virus vaccines is not recommended for at least 6&nbsp;weeks prior to the start of lymphodepleting chemotherapy, during CARVYKTI treatment, and until immune recovery following treatment with CARVYKTI.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception in males and females</u></p><p>Pregnancy status for females of childbearing potential should be verified prior to starting treatment with CARVYKTI.</p><p>There are insufficient exposure data to provide a recommendation concerning duration of contraception following treatment with CARVYKTI.</p><p>&nbsp;</p><p>In clinical trials, female patients of childbearing potential were advised to practice a highly effective method of contraception, and male patients with partners of childbearing potential or whose partners were pregnant were instructed to use a barrier method of contraception, until one year after the patient has received CARVYKTI.</p><p>&nbsp;</p><p>See the prescribing information for lymphodepleting chemotherapy for information on the need for contraception in patients who receive the lymphodepleting chemotherapy.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>There are no available data on the use of CARVYKTI in pregnant women. No reproductive and developmental toxicity animal studies have been conducted with CARVYKTI. It is not known whether CARVYKTI has the potential to be transferred to the foetus and cause foetal toxicity.</p><p>&nbsp;</p><p>Therefore, CARVYKTI is not recommended for women who are pregnant, or for women of childbearing potential not using contraception. Pregnant women should be advised there may be risks to the foetus. Pregnancy after CARVYKTI therapy should be discussed with the treating physician.</p><p>&nbsp;</p><p>Pregnant women who have received CARVYKTI may have hypogammaglobulinaemia. Assessment of immunoglobulin levels in newborns of mothers treated with CARVYKTI should be considered.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is unknown whether CARVYKTI is excreted in human milk. Women who are breast-feeding should be advised of the potential risk to the breast-fed infant.</p><p>Following administration of CARVYKTI, the decision to consider breast-feeding should be discussed with the treating physician.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There are no data on the effect of CARVYKTI on fertility. Effects of CARVYKTI on male and female fertility have not been evaluated in animal studies (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>CARVYKTI has major influence on the ability to drive and use machines.</p><p>Due to the potential for neurologic events, patients receiving CARVYKTI are at risk for altered or decreased consciousness or coordination in the 8&nbsp;weeks following CARVYKTI infusion (see section&nbsp;4.4). Patients should be advised to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery during this initial period, and in the event of new onset of any neurological symptoms.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The safety of CARVYKTI was evaluated in 396&nbsp;adult patients with multiple myeloma infused with CARVYKTI in three open label clinical trials: Study MMY2001 (N=106), which included patients from the main Phase 1b/2&nbsp;cohort (United States; n=97) and an additional cohort (Japan; n=9), Phase&nbsp;2 Study MMY2003 (N=94) and Phase&nbsp;3 Study MMY3002 (N=196).</p><p>&nbsp;</p><p>The most common CARVYKTI adverse reactions (&ge;20%) were neutropenia (89%), pyrexia&nbsp;(84%), CRS (83%), thrombocytopenia (60%), anemia (60%), musculoskeletal pain (38%), fatigue (35%), lymphopenia (34%), leukopenia (33%), hypotension (33%), diarrhea (31%), upper respiratory tract infection (30%), hypogammaglobulinaemia (29%), transaminase elevation (25%), headache (24%), nausea (23%), and cough (21%).</p><p><em>&nbsp;</em></p><p>Serious adverse reactions occurred in 41% of patients; serious adverse reactions reported in &ge;2% of patients were CRS (11%), pneumonia (7%), sepsis (5%), viral infection (4%), neutropenia (4%), cranial nerve palsies, (4%), ICANS (4%), encephalopathy (3%), bacterial infections (2%), upper respiratory tract infection (2%), gastroenteritis (2%), febrile neutropenia (2%), thrombocytopenia (2%), haemophagocytic lymphohistiocytosis (2%), motor dysfunction (2%), dyspnea (2%), diarrhea (2%), and renal failure (2%).</p><p>&nbsp;</p><p>The most common (&ge;5%) Grade&nbsp;&ge;&nbsp;3 non-haematological adverse reactions were transaminase elevation (11%), pneumonia (9%), febrile neutropenia (8%), sepsis (7%), Gamma-glutamyltransferase increased (6%), hypotension (6%), pyrexia (6%), bacterial infection (5%), and hypogammaglobulinaemia (5%).</p><p>&nbsp;</p><p>The most common (&ge;20%) Grade&nbsp;&ge;3 haematological abnormalities were neutropenia (88%), thrombocytopenia (44%), anaemia (44%), lymphopenia (33%), and leukopenia (32%).</p><p><em>&nbsp;</em></p><p><u>Tabulated list of adverse reactions</u></p><p>Table&nbsp;4 summarises the adverse reactions that occurred in patients receiving CARVYKTI.</p><p>Within each system organ class, the adverse reactions are ranked by frequency. Within each frequency grouping, where relevant, adverse reactions are presented in order of decreasing seriousness using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p><em>&nbsp;</em></p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="5" style="vertical-align:bottom"><p><strong>Table&nbsp;4:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reaction in patients with multiple myeloma treated with CARVYKTI </strong></p></td></tr><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>System organ class </strong></p></td><td rowspan="2" style="vertical-align:bottom"><p><strong>Frequency </strong></p></td><td rowspan="2" style="vertical-align:bottom"><p><strong>Adverse Reaction </strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Incidence (%) </strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>All grades </strong></p></td><td style="vertical-align:bottom"><p><strong>grade</strong>&nbsp;<strong>&ge;</strong>&nbsp;<strong>3</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td rowspan="4" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Bacterial infection<sup>*# </sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Upper respiratory tract infection<sup>*</sup></p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Viral infection<sup>*</sup></p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Pneumonia<sup>*#</sup></p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td rowspan="3" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Sepsis<sup>1#</sup></p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Gastroenteritis<sup>2</sup></p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Urinary tract infection<sup>3</sup></p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fungal infection<sup>*</sup></p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Neoplasms benign, malignant and unspecified (including cysts and polyps)</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Secondary malignancy of T-cell origin</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Neutropenia<sup>*</sup></p></td><td style="vertical-align:top"><p>89</p></td><td style="vertical-align:top"><p>88</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>44</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaemia<sup>4</sup></p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>44</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Leukopenia</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>32</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lymphopenia</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>33</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Coagulopathy<sup>5</sup></p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Febrile neutropenia</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lymphocytosis<sup>6</sup></p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hypogammaglobulinaemia<sup>*</sup></p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cytokine release syndrome<sup>#</sup></p></td><td style="vertical-align:top"><p>83</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Haemophagocytic lymphohistiocytosis<sup>#</sup></p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hypocalcaemia</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypophosphataemia</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypokalaemia</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypoalbuminaemia</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyponatraemia</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypomagnesaemia</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperferritinemia<sup>7</sup></p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Delirium<sup>8</sup></p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Personality changes<sup>9</sup></p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Encephalopathy<sup>10#</sup></p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Immune effector cell-associated neurotoxicity syndrome<sup>#</sup></p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Motor dysfunction<sup>11</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dizziness<sup>*</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sleep disorder<sup>12</sup></p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Aphasia<sup>13</sup></p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cranial nerve palsies<sup>14</sup></p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Paresis<sup>15</sup></p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ataxia<sup>16</sup></p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tremor<sup>*</sup></p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Neurotoxicity<sup>#</sup></p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Neuropathy peripheral<sup>17</sup></p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Guillain-Barre syndrome</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Tachycardia<sup>*</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Cardiac arrhythmias<sup>18</sup></p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td rowspan="3" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hypotension<sup>*</sup></p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>Haemorrhage<sup>19#</sup></p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Thrombosis<sup>*</sup></p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Capillary leak syndrome</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hypoxia<sup>*</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea<sup>20#</sup></p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cough<sup>*</sup></p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Diarrhoea<sup>21</sup></p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Abdominal pain<sup>*</sup></p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hyperbilirubinaemia</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rash<sup>*</sup></p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Musculoskeletal pain<sup>*</sup></p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Renal failure<sup>22</sup></p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td rowspan="3" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>84</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>*</sup></p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>Chills</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oedema<sup>23</sup></p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pain<sup>*</sup></p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Transaminase elevation<sup>*</sup></p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gamma-glutamyltransferase increased</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td rowspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>C-reactive protein increased</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Blood alkaline phosphatase increased</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Adverse reactions are reported using MedDRA version&nbsp;25.0</p><p><sup>#</sup>&nbsp;&nbsp;&nbsp;&nbsp; Contains fatal outcome(s).</p><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp; Based on grouped term.</p><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp; Sepsis includes bacteraemia, bacterial sepsis, candida sepsis, device related bacteraemia, enterococcal bacteraemia, haemophilus sepsis, neutropenic sepsis, pseudomonal bacteraemia, pseudomonal sepsis, sepsis, septic shock, staphylococcal bacteraemia, streptococcal sepsis, systemic candida, and urosepsis.</p><p><sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp; Gastroenteritis includes enterocolitis bacterial, enterocolitis infectious, enterocolitis viral, enterovirus infection, gastroenteritis, gastroenteritis cryptosporidial, gastroenteritis rotavirus, gastroenteritis salmonella, gastroenteritis viral, gastrointestinal infection, and large intestine infection.</p><p><sup>3</sup>&nbsp;&nbsp;&nbsp;&nbsp; Urinary tract infection includes cystitis, escherichia urinary tract infection, urinary tract infection, urinary tract infection bacterial, and urinary tract infection viral.</p><p><sup>4</sup>&nbsp;&nbsp;&nbsp;&nbsp; Anaemia includes anaemia, and iron deficiency anaemia.</p><p><sup>5</sup>&nbsp;&nbsp;&nbsp;&nbsp; Coagulopathy includes activated partial thromboplastin time prolonged, blood fibrinogen decreased, coagulation test abnormal, coagulopathy, disseminated intravascular coagulation, hypofibrinogenaemia, international normalised ratio increased, prothrombin level increased, and prothrombin time prolonged.</p><p><sup>6</sup>&nbsp;&nbsp;&nbsp;&nbsp; Lymphocytosis includes lymphocyte count increased, and lymphocytosis.</p><p><sup>7</sup>&nbsp;&nbsp;&nbsp;&nbsp; Hyperferritinemia includes hyperferritinaemia, and serum ferritin increased.</p><p><sup>8</sup>&nbsp;&nbsp;&nbsp;&nbsp; Delirium includes agitation, delirium, disorientation, euphoric mood, hallucination, irritability, and restlessness.</p><p><sup>9</sup>&nbsp;&nbsp;&nbsp;&nbsp; Personality changes includes flat affect, indifference, personality change, and reduced facial expression.</p><p><sup>10</sup>&nbsp;&nbsp; Encephalopathy includes amnesia, bradyphrenia, confusional state, depressed level of consciousness, disturbance in attention, encephalopathy, lethargy, memory impairment, mental impairment, mental status changes, psychomotor retardation, and slow response to stimuli.</p><p><sup>11</sup>&nbsp;&nbsp; Motor dysfunction includes agraphia, dysgraphia, eyelid ptosis, micrographia, motor dysfunction, muscle rigidity, muscle spasms, muscle tightness, muscular weakness, myoclonus, and parkinsonism.</p><p><sup>12</sup>&nbsp;&nbsp; Sleep disorder includes hypersomnia, insomnia, sleep disorder, and somnolence.</p><p><sup>13</sup>&nbsp;&nbsp; Aphasia includes aphasia, dysarthria, slow speech, and speech disorder.</p><p><sup>14</sup>&nbsp;&nbsp; Cranial nerve palsies include Bell`s palsy, cranial nerve paralysis, facial nerve disorder, facial paralysis, facial paresis, III<sup>rd</sup> nerve paralysis, trigeminal palsy, and VI<sup>th</sup> nerve paralysis.</p><p><sup>15</sup>&nbsp;&nbsp; Paresis includes hemiparesis, paresis, and peroneal nerve palsy.</p><p><sup>16</sup>&nbsp;&nbsp; Ataxia includes ataxia, balance disorder, dysmetria, and gait disturbance.</p><p><sup>17</sup>&nbsp;&nbsp; Neuropathy peripheral includes neuropathy peripheral, peripheral motor neuropathy, peripheral sensorimotor neuropathy, peripheral sensory neuropathy, and polyneuropathy.</p><p><sup>18</sup>&nbsp;&nbsp; Cardiac arrhythmias include atrial fibrillation, atrial flutter, atrioventricular block second degree, supraventricular tachycardia, ventricular extrasystoles, and ventricular tachycardia.</p><p><sup>19</sup>&nbsp;&nbsp; Haemorrhage includes catheter site haemorrhage, cerebral haemorrhage, conjunctival haemorrhage, contusion, epistaxis, eye contusion, haematemesis, haematochezia, haematoma, haematuria, haemoptysis, lower gastrointestinal haemorrhage, pulmonary haemorrhage, retinal haemorrhage, retroperitoneal haemorrhage, subarachnoid haemorrhage, and Subdural haematoma.</p><p><sup>20</sup>&nbsp;&nbsp; Dyspnoea includes acute respiratory failure, dyspnoea, dyspnoea exertional, respiratory failure, tachyponea and wheezing.</p><p><sup>21</sup>&nbsp;&nbsp; Diarrhoea includes colitis, and diarrhoea.</p><p><sup>22</sup>&nbsp;&nbsp; Renal failure includes acute kidney injury, blood creatinine increased, chronic kidney disease, renal failure, and renal impairment.</p><p><sup>23</sup>&nbsp;&nbsp; Oedema includes face oedema, fluid retention, generalised oedema, hypervolaemia, &nbsp;localised oedema, oedema, oedema peripheral, palatal oedema, periorbital oedema, peripheral swelling, pulmonary congestion, and pulmonary oedema.</p><p>&nbsp;</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p>Of the 196&nbsp;patients in Study MMY3002, 20&nbsp;patients who had higher risk disease progressed early and rapidly on bridging therapy prior to infusion with CARVYKTI and received CARVYKTI as subsequent therapy (see<em> </em>section 5.1). In these patients, MNT was reported in one patient (5%) and was mild in severity (Grade 1 or 2). CRS was reported at a higher rate for Grade 3 and Grade 4 (25%), including events of CRS complicated by HLH (10%) or DIC (10%). ICANS was reported at a higher rate (35%) and severity (10%) for Grade 3. Five patients died of fatal events related to CARVYKTI (2 due to haemorrhage in the context of HLH or DIC and 3 due to fatal infections).</p><p><u>&nbsp;</u></p><p><u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p><em>Cytokine release syndrome</em></p><p>CRS was reported in 83% of patients (n=330); 79% (n=314) of patients had CRS events that were Grade&nbsp;1 or Grade&nbsp;2, 4% (n=15) of patients had Grade&nbsp;3 or Grade&nbsp;4 CRS events and &lt;1% (n=1) of patients had a Grade&nbsp;5 CRS event. Ninety-eight percent of patients (n=323) recovered from CRS. The duration of CRS was &le;18&nbsp;days for all but one patient, who had a duration of CRS of 97&nbsp;days, complicated by secondary HLH with a subsequent fatal outcome. The most frequent (&ge;10%) signs or symptoms associated with CRS included pyrexia (81%), hypotension (28%), Aspartate aminotransferase (AST) increased (12%), and hypoxia (10%). See section&nbsp;4.4 for monitoring and management guidance.</p><p><em>&nbsp;</em></p><p><em>Neurologic toxicities</em></p><p>Neurologic toxicity occurred in 23% of patients (n=89); 5% (n=21) of patients had Grade&nbsp;3 or Grade&nbsp;4 neurologic toxicity and 1% (n=3) of patients had Grade&nbsp;5 neurologic toxicity (one due to ICANS, one due to neurologic toxicity with ongoing parkinsonism, and one due to encephalopathy). In addition, eleven&nbsp;patients had fatal outcomes with ongoing neurologic toxicity at the time of death; eight&nbsp;deaths were due to infection (including two deaths in patients with ongoing signs and symptoms of parkinsonism, as discussed below), and one death each due to respiratory failure, cardio-respiratory arrest and intraparenchymal hemorrhage. See section&nbsp;4.4 for monitoring and management guidance.</p><p>&nbsp;</p><p><em>Immune effector cell-associated neurotoxicity syndrome (ICANS)</em></p><p>In the pooled studies (N=396), ICANS occurred in 11% of patients (n=45), with 2% (n=7) experiencing Grade&nbsp;3 or 4 ICANS and &lt;1% (n=1) Grade 5 ICANS. Symptoms included aphasia, slow speech, dysgraphia, encephalopathy, depressed level of consciousness and confusional state. The median time from CARVYKTI infusion to first onset of ICANS was 8&nbsp;days (range: 2 to 15&nbsp;days, except for 1 patient with onset at 26&nbsp;days) and the median duration was 3&nbsp;days (range: 1 to 29&nbsp;days, except for 1 patient who had a subsequent fatal outcome at 40&nbsp;days).</p><p>&nbsp;</p><p><em>Movement and neurocognitive toxicity with signs and symptoms of parkinsonism</em></p><p>Of the 89&nbsp;patients in the pooled studies (N=396) experiencing any neurotoxicity, nine male patients had neurologic toxicity with several signs and symptoms of parkinsonism, distinct from ICANS. The maximum toxicity grades of parkinsonism were: Grade 1 (n=1), Grade&nbsp;2 (n=2), Grade&nbsp;3 (n=6). The median onset of parkinsonism was 38.0&nbsp;days (range: 14 to 914&nbsp;days) from infusion of CARVYKTI. One patient (Grade&nbsp;3) died of neurologic toxicity with ongoing parkinsonism 247&nbsp;days after administration of CARVYKTI, and two patients (Grade&nbsp;2 and Grade&nbsp;3) with ongoing parkinsonism died of infectious causes 162 and 119&nbsp;days after administration of CARVYKTI. One patient recovered (Grade 3). The remaining 5&nbsp;patients, symptoms of parkinsonism were ongoing up to 996&nbsp;days after administration of CARVYKTI.<em> </em>All 9&nbsp;patients had a history of prior CRS (n=1 Grade&nbsp;1; n=6 Grade&nbsp;2; n=1 Grade&nbsp;3; n=1 Grade&nbsp;4), while 6 of 9&nbsp;patients had prior ICANS (n=5 Grade&nbsp;1; n=1 Grade&nbsp;3).</p><p>&nbsp;</p><p><em>Guillain-Barr&eacute; syndrome</em></p><p>In the pooled studies (N=396), one patient was reported to have GBS after treatment with CARVYKTI. Although GBS symptoms improved after receiving treatment with steroids and IVIG, the patient died 139&nbsp;days after administration of CARVYKTI due to encephalopathy post gastroenteritis with ongoing GBS symptoms.</p><p>&nbsp;</p><p><em>Peripheral neuropathy</em></p><p>In the pooled studies (N=396), 27&nbsp;patients developed peripheral neuropathy, presenting as sensory, motor, or sensorimotor neuropathies. Median time of onset of symptoms was 57&nbsp;days (range: 1 to 914&nbsp;days), median duration of peripheral neuropathies was 140&nbsp;days (range: 1 to 766&nbsp;days) including those with ongoing neuropathy. Of these 27&nbsp;patients, 5 experienced Grade&nbsp;3 or Grade&nbsp;4 peripheral neuropathy (which resolved in 1&nbsp;patient with no treatment reported, and was ongoing in the other 4&nbsp;patients, including one patient who improved after treatment with dexamethasone). Of the remaining 22 with &le;&nbsp;Grade&nbsp;2 peripheral neuropathy, peripheral neuropathy resolved with no treatment reported in 6&nbsp;patients and following treatment with duloxetine in 2&nbsp;patients, and was ongoing in the other 10&nbsp;patients.</p><p>&nbsp;</p><p><em>Cranial nerve palsies</em></p><p>In the pooled studies (N=396), 27&nbsp;patients experienced cranial nerve palsies. Median time to onset was 22&nbsp;days (range: 17 to 101&nbsp;days) following infusion of CARVYKTI, and median time to resolution was 56&nbsp;days (range: 1 to 209&nbsp;days) following onset of symptoms.</p><p>&nbsp;</p><p><em>Prolonged and recurrent cytopenias</em></p><p>Grade&nbsp;3 or 4&nbsp;cytopenias at Day&nbsp;1 after dosing, not resolved to Grade&nbsp;2 or lower by Day&nbsp;30 following CARVYKTI infusion, included, thrombocytopenia (33%), neutropenia (29%), lymphopenia (25%), and anemia (3%). After Day&nbsp;60 following CARVYKTI, 23%, 21%, 7%, and 4% of patients had an occurrence of Grade&nbsp;3 or 4&nbsp;lymphopenia, neutropenia, anemia, and thrombocytopenia respectively, after initial recovery of their Grade&nbsp;3 or 4&nbsp;cytopenia.</p><p>&nbsp;</p><p>Table&nbsp;5 lists the incidences of Grade&nbsp;3 or Grade 4&nbsp;cytopenias occurring after dosing not resolved to Grade&nbsp;2 or lower by Day&nbsp;30 and Day&nbsp;60, respectively.</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:623px"><tbody><tr><td colspan="5" style="vertical-align:bottom"><p><strong>Table&nbsp;5:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Incidences of prolonged and recurrent cytopenias following treatment with CARVYKTI (N=396)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:bottom"><p><strong>Grade&nbsp;3/4 (%) after Day&nbsp;1 dosing</strong></p></td><td style="vertical-align:bottom"><p><strong>Initial Grade&nbsp;3/4 (%) not recovered<sup>a</sup> to &le;Grade&nbsp;2 by Day&nbsp;30</strong></p></td><td style="vertical-align:top"><p><strong>Initial Grade&nbsp;3/4 (%) not recovered<sup>a</sup> to &le;Grade&nbsp;2 by Day&nbsp;60 </strong></p></td><td style="vertical-align:bottom"><p><strong>Occurrence of Grade&nbsp;3/4 (%) &gt;&nbsp;Day&nbsp;60 (after initial recovery<sup>a</sup> of Grade&nbsp;3/4)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:bottom"><p>191 (48%)</p></td><td style="vertical-align:bottom"><p>132 (33%)</p></td><td style="vertical-align:bottom"><p>76 (19%)</p></td><td style="vertical-align:bottom"><p>14 (4%)</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia</p></td><td style="vertical-align:bottom"><p>381 (96%)</p></td><td style="vertical-align:bottom"><p>114 (29%)</p></td><td style="vertical-align:bottom"><p>44 (11%)</p></td><td style="vertical-align:bottom"><p>81 (21%)</p></td></tr><tr><td style="vertical-align:top"><p>Lymphopenia</p></td><td style="vertical-align:bottom"><p>391 (99%)</p></td><td style="vertical-align:bottom"><p>98 (25%)</p></td><td style="vertical-align:bottom"><p>46 (12%)</p></td><td style="vertical-align:bottom"><p>90 (23%)</p></td></tr><tr><td style="vertical-align:top"><p>Anemia</p></td><td style="vertical-align:bottom"><p>180 (46%)</p></td><td style="vertical-align:bottom"><p>11 (3%)</p></td><td style="vertical-align:bottom"><p>12 (3%)</p></td><td style="vertical-align:bottom"><p>26 (7%)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>The laboratory result with the worst toxicity grade is used for a calendar day. Recovery definition: must have 2 consecutive Grade &le;&nbsp;2 results on different days if recovery period &le;10&nbsp;days.</p><p>Notes: Lab results assessed after Day&nbsp;1 until Day&nbsp;100 for MMY2001 and MMY2003 or Day 112 for MMY3002, or the start of subsequent therapy, whichever occurs first, are included in the analysis.</p><p>Thrombocytopenia: Grade&nbsp;3/4 &ndash; Platelets count &lt;&nbsp;50,000&nbsp;cells/&micro;L.</p><p>Neutropenia: Grade&nbsp;3/4 &ndash; Neutrophil count &lt;&nbsp;1,000&nbsp;cells/&micro;L.</p><p>Lymphopenia: Grade&nbsp;3/4 &ndash; &nbsp;Lymphocytes count &lt;&nbsp;0.5&times;10<sup>9&nbsp;</sup>cells/L.</p><p>Anemia: Grade 3 &ndash; hemoglobin &lt;8g/dL. Grade 4 not defined by laboratory count per NCI-CTCAE v5.</p><p>Percentages are based on the number of treated patients.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Serious infections</em></p><p>Infections occurred in 52% of patients (n=206); 17% of patients (n=66) experienced Grade&nbsp;3 or Grade&nbsp;4 infections, and fatal infections (COVID-19 pneumonia, pneumonia, sepsis, <em>Clostridium difficile</em> colitis, septic shock, bronchopulmonary aspergillosis, pseudomonal sepsis, neutropenic sepsis, and lung abscess) occurred in 4% of patients (n=17). The most frequently reported (&ge;&nbsp;2%) Grade&nbsp;3 or higher infections were pneumonia, COVID-19 pneumonia, and sepsis. Febrile neutropenia was observed in 6% of patients with 2% experiencing serious febrile neutropenia.</p><p>See section&nbsp;4.4 for monitoring and management guidance.</p><p>&nbsp;</p><p><em>Hypogammaglobulinaemia</em></p><p>In the pooled studies (N=396), hypogammaglobulinaemia occurred in 30% of patients, with 5% of patients experiencing Grade&nbsp;3 hypogammaglobulinaemia. Laboratory IgG levels fell below 500&nbsp;mg/dL after infusion in 91% (359/396) of patients treated with CARVYKTI. Hypogammaglobulinaemia either as an adverse reaction or a laboratory IgG level below 500&nbsp;mg/dL occurred in 92% (363/396) of patients after infusion. Fifty-three percent of patients received IVIG post CARVYKTI for either an adverse reaction or prophylaxis. See section&nbsp;4.4 for monitoring and management guidance.</p><p>&nbsp;</p><p><em>Immunogenicity</em></p><p>The immunogenicity of CARVYKTI has been evaluated using a validated assay for the detection of binding antibodies against CARVYKTI pre-dose, and at multiple timepoints post-infusion. In the pooled studies (n=363), 23% (83/363) of patients with appropriate samples were positive for treatment-emergent anti-CAR antibodies. There was no clear evidence that the observed anti-CAR antibodies impact CARVYKTI kinetics of initial expansion and persistence, efficacy or safety.</p><p>&nbsp;</p><p><strong>4.8.2: Clinical Studies Experience</strong></p><p>&nbsp;</p><p>Additional adverse reactions from Study MMY2001 (based on USA cohort, N=97) added upon the request from the Saudi Food and Drug Authority include chest pain (7%), tremor (6%), hypersensitivity reactions (5%), depression (4.1%), fall (3.1%), diplopia (1%), dysphagia (1%), tumor lysis syndrome (1%), seizure (1%), nystagmus (1%), and cerebrovascular accident (1%)</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>To report any side effect(s):</u></p><p><u>&nbsp;</u></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia: </strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data regarding the signs or sequelae of overdose with CARVYKTI.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, other antineoplastic agents, ATC code: L01XL05</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>CARVYKTI is a BCMA-directed, genetically modified autologous T cell immunotherapy, which involves reprogramming a patient&rsquo;s own T cells with a transgene encoding a chimeric antigen receptor (CAR) that identifies and eliminates cells that express BCMA. BCMA is primarily expressed on the surface of malignant multiple myeloma B-lineage cells, as well as late-stage B cells and plasma cells. The CARVYKTI CAR protein features<em> </em>two BCMA-targeting<strong> </strong>single domain antibodies<strong> </strong>designed to confer high avidity against human BCMA, a 4-1BB co-stimulatory domain and a CD3‑zeta (CD3&zeta;) signaling cytoplasmic domain. Upon binding to BCMA expressing cells, the CAR promotes T cell activation, expansion, and elimination of target cells.</p><p><em>&nbsp;</em></p><p><u>Pharmacodynamic effects</u></p><p><em>In vitro</em> co-culture experiments demonstrated that ciltacabtagene autoleucel-mediated cytotoxicity and cytokine release (interferon-gamma, [IFN-&gamma;], tumour necrosis factor alpha [TNF-&alpha;], interleukin [IL]-2) were BCMA-dependent.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em>CARTITUDE-1 (Study MMY2001)</em></p><p>MMY2001 was an open label, single-arm, multicentre, Phase 1b/2&nbsp;study evaluating the efficacy and safety of CARVYKTI for the treatment of adult patients with relapsed and refractory multiple myeloma who had received at least 3 prior lines of antimyeloma therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38&nbsp;antibody and who had disease progression on or within 12&nbsp;months after the last regimen. Patients with known active, or prior history of significant central nervous system (CNS) disease including CNS multiple myeloma, patients previously exposed to other anti-BCMA treatments, allogeneic stem cell transplant within 6&nbsp;months before apheresis or ongoing treatment with immunosuppressants, creatinine clearance &lt;&nbsp;40&nbsp;mL/min, absolute lymphocyte concentration &lt;&nbsp;300/&micro;L, hepatic transaminases &gt;&nbsp;3 times the upper limit of normal, cardiac ejection fraction &lt;&nbsp;45%, or with active serious infection were excluded from the trial.</p><p>&nbsp;</p><p>In total, 113&nbsp;patients underwent leukapheresis; CARVYKTI was manufactured for all patients. Sixteen&nbsp;patients were not treated with CARVYKTI (n=12 after leukapheresis and n=4 after lymphodepleting therapy), due to either withdrawal by patient (n=5), progressive disease (n=2) or death (n=9).</p><p>&nbsp;</p><p>Of the 97&nbsp;patients treated, the median time from the day after receipt of leukapheresis material at manufacturing facility to release of medicinal product for infusion was 29&nbsp;days (range: 23 to 64&nbsp;days) and the median time from initial leukapheresis to CARVYKTI infusion was 47&nbsp;days (range: 41 to 167&nbsp;days).</p><p>&nbsp;</p><p>Following leukapheresis and prior to administration of CARVYKTI, 73 of the 97&nbsp;patients (75%) received bridging therapy. The most commonly used agents as bridging therapies (&ge;20% of patients) included dexamethasone: 62&nbsp;patients&nbsp;(63.9%), bortezomib: 26&nbsp;patients (26.8%), cyclophosphamide: 22&nbsp;patients (22.7%), and pomalidomide: 21&nbsp;patients (21.6%).</p><p>&nbsp;</p><p>CARVYKTI was administered as a single IV infusion 5 to 7&nbsp;days after the start of a lymphodepleting chemotherapy (cyclophosphamide 300&nbsp;mg/m<sup>2</sup> intravenously daily and fludarabine 30&nbsp;mg/m<sup>2</sup> intravenously daily for 3&nbsp;days). Ninety-seven patients received CARVYKTI at a median dose of 0.71&nbsp;&times;&nbsp;10<sup>6</sup>&nbsp;CAR-positive viable T cells/kg (range: 0.51 to 0.95&nbsp;&times;&nbsp;10<sup>6</sup>&nbsp;cells/kg). All patients were hospitalised for the CARVYKTI infusion and for a minimum of 10&nbsp;days afterward.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;6: Summary of patient demographic and baseline characteristics</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Analysis set </strong></p></td><td style="vertical-align:top"><p><strong>All Treated<br />(N=97)</strong></p></td><td style="vertical-align:top"><p><strong>All Leukapheresed</strong></p><p><strong>(N=113)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Age (years)</strong></p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Category n (%)</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&lt;&nbsp;65</p></td><td style="vertical-align:bottom"><p>62 (64)</p></td><td style="vertical-align:top"><p>70 (62)</p></td></tr><tr><td style="vertical-align:top"><p>65&nbsp;&ndash;&nbsp;75</p></td><td style="vertical-align:bottom"><p>27 (28)</p></td><td style="vertical-align:top"><p>34 (30)</p></td></tr><tr><td style="vertical-align:top"><p>&gt;&nbsp;75</p></td><td style="vertical-align:bottom"><p>8 (8)</p></td><td style="vertical-align:top"><p>9 (8)</p></td></tr><tr><td style="vertical-align:top"><p>Median (range)</p></td><td style="vertical-align:bottom"><p>61.0 (43; 78)</p></td><td style="vertical-align:top"><p>62 (29; 78)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Sex</strong></p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Male n (%)</p></td><td style="vertical-align:bottom"><p>57 (59)</p></td><td style="vertical-align:top"><p>65 (57.5)</p></td></tr><tr><td style="vertical-align:top"><p>Female n (%)</p></td><td style="vertical-align:bottom"><p>40 (41)</p></td><td style="vertical-align:top"><p>48 (42.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Race</strong></p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>American Indian or Alaska native</p></td><td style="vertical-align:bottom"><p>1 (1)</p></td><td style="vertical-align:top"><p>1 (1)</p></td></tr><tr><td style="vertical-align:top"><p>Asian</p></td><td style="vertical-align:bottom"><p>1 (1)</p></td><td style="vertical-align:top"><p>1 (1)</p></td></tr><tr><td style="vertical-align:top"><p>Black or African American</p></td><td style="vertical-align:bottom"><p>17 (17.5)</p></td><td style="vertical-align:top"><p>17 (15)</p></td></tr><tr><td style="vertical-align:top"><p>Native Hawaiian or other Pacific islander</p></td><td style="vertical-align:bottom"><p>1 (1)</p></td><td style="vertical-align:top"><p>1 (1)</p></td></tr><tr><td style="vertical-align:top"><p>White</p></td><td style="vertical-align:bottom"><p>69 (71)</p></td><td style="vertical-align:top"><p>83 (73.5)</p></td></tr><tr><td style="vertical-align:top"><p>Multiple</p></td><td style="vertical-align:bottom"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Not reported</p></td><td style="vertical-align:bottom"><p>8 (8)</p></td><td style="vertical-align:top"><p>10 (9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>ECOG score prior to infusion n (%)</strong></p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:bottom"><p>39 (40)</p></td><td style="vertical-align:top"><p>55 (49)</p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:bottom"><p>54 (56)</p></td><td style="vertical-align:top"><p>58 (51)</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:bottom"><p>4 (4)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>ISS staging at study baseline n (%)</strong></p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:bottom"><p>97</p></td><td style="vertical-align:top"><p>58</p></td></tr><tr><td style="vertical-align:top"><p>I</p></td><td style="vertical-align:bottom"><p>61 (63)</p></td><td style="vertical-align:top"><p>32 (55)</p></td></tr><tr><td style="vertical-align:top"><p>II</p></td><td style="vertical-align:bottom"><p>22 (23)</p></td><td style="vertical-align:top"><p>21 (36)</p></td></tr><tr><td style="vertical-align:top"><p>III</p></td><td style="vertical-align:bottom"><p>14 (14)</p></td><td style="vertical-align:top"><p>5 (9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Creatinine Clearance/eGFR (MDRD) (mL/min/1.73&nbsp;m<sup>2</sup>)</strong></p><p>Median (range)</p></td><td style="vertical-align:bottom"><p>88.44 (41.8, 242.9)</p></td><td style="vertical-align:top"><p>73.61 (36.2, 177.8)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Time since initial multiple myeloma diagnosis to enrollment (years)</strong></p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median (range)</p></td><td style="vertical-align:bottom"><p>5.94 (1.6; 18.2)</p></td><td style="vertical-align:top"><p>5.73 (1.0; 18.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Presence of extramedullary plasmacytomas n (%)</strong></p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Yes</p></td><td style="vertical-align:bottom"><p>13 (13)</p></td><td style="vertical-align:top"><p>NA<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>No</p></td><td style="vertical-align:bottom"><p>84 (87)</p></td><td style="vertical-align:top"><p>NA<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Cytogenetic risk at study baseline n (%)</strong></p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Standard risk</p></td><td style="vertical-align:bottom"><p>68 (70)</p></td><td style="vertical-align:top"><p>70 (62)</p></td></tr><tr><td style="vertical-align:top"><p>High risk</p></td><td style="vertical-align:bottom"><p>23 (24)</p></td><td style="vertical-align:top"><p>28 (25)</p></td></tr><tr><td style="vertical-align:top"><p>Del17p</p></td><td style="vertical-align:bottom"><p>19 (20)</p></td><td style="vertical-align:top"><p>22 (19.5)</p></td></tr><tr><td style="vertical-align:top"><p>T(4;14)</p></td><td style="vertical-align:bottom"><p>3 (3)</p></td><td style="vertical-align:top"><p>5 (4)</p></td></tr><tr><td style="vertical-align:top"><p>T(14;16)</p></td><td style="vertical-align:bottom"><p>2 (2)</p></td><td style="vertical-align:top"><p>3 (3)</p></td></tr><tr><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:bottom"><p>6 (6)</p></td><td style="vertical-align:top"><p>15 (13)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Tumour BCMA expression (%)</strong></p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median (range)</p></td><td style="vertical-align:bottom"><p>80 (20; 98)</p></td><td style="vertical-align:top"><p>80 (20; 98)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of lines of prior therapies for multiple myeloma</strong></p><p>Median (range)</p></td><td style="vertical-align:bottom"><p>6 (3,18)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>5 (3, 18)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Prior treatment with PI+IMiD+anti-CD38</strong>&nbsp;<strong>antibodies </strong><strong>n (%)</strong></p></td><td style="vertical-align:bottom"><p>97 (100)</p></td><td style="vertical-align:bottom"><p>113 (100)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Prior autologous SCT</strong><strong> n (%)</strong></p></td><td style="vertical-align:bottom"><p>87 (90)</p></td><td style="vertical-align:top"><p>99 (88)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Prior allogeneic SCT</strong><strong> n (%)</strong></p></td><td style="vertical-align:bottom"><p>8 (8)</p></td><td style="vertical-align:top"><p>8 (7)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Refractory at any point to prior therapy</strong><strong> n (%)</strong></p></td><td style="vertical-align:bottom"><p>97 (100)</p></td><td style="vertical-align:top"><p>113 (100)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Refractory to PI+IMiD+anti-CD38</strong>&nbsp;<strong>antibody</strong><strong> n (%)</strong></p></td><td style="vertical-align:bottom"><p>85 (88)</p></td><td style="vertical-align:top"><p>100 (88.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Refractory to last line of prior therapy</strong><strong> n (%)</strong></p></td><td style="vertical-align:bottom"><p>96 (99)</p></td><td style="vertical-align:top"><p>112 (99)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>ECOG= Eastern Cooperative Oncology Group; ISS= International Staging System; PI= Proteasome inhibitor; IMiD= Immunomodulatory drug; SCT= Stem cell transplant; NA= not applicable.</p><p><sup>a</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Plasmacytomas were not assessed until prior to lymphodepletion.</p></td></tr></tbody></table><p>&nbsp;</p><p>Efficacy results were based on overall response rate as determined by the Independent Review Committee assessment using IMWG criteria (see Table&nbsp;7).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="3" style="vertical-align:bottom"><p><strong>Table&nbsp;7:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy results for Study MMY2001</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Analysis set </strong></p></td><td style="vertical-align:top"><p><strong>All Treated</strong></p><p><strong>(N=97)</strong></p></td><td style="vertical-align:top"><p><strong>All Leukapheresed</strong></p><p><strong>(N=113)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Overall Response Rate (sCR<sup>a</sup> + VGPR + PR) n (%)</strong></p></td><td style="vertical-align:top"><p>95 (97.9)</p></td><td style="vertical-align:top"><p>95 (84.1)</p></td></tr><tr><td style="vertical-align:top"><p>95% CI (%)</p></td><td style="vertical-align:top"><p>(92.7, 99.7)</p></td><td style="vertical-align:top"><p>(76.0, 90.3)</p></td></tr><tr><td style="vertical-align:top"><p>Stringent complete response (sCR)<sup>a</sup> n (%)</p></td><td style="vertical-align:top"><p>80 (82.5)</p></td><td style="vertical-align:top"><p>80 (70.8)</p></td></tr><tr><td style="vertical-align:top"><p>Very good partial response (VGPR) n (%)</p></td><td style="vertical-align:top"><p>12 (12.4)</p></td><td style="vertical-align:top"><p>12 (10.6)</p></td></tr><tr><td style="vertical-align:top"><p>Partial response (PR) n (%)</p></td><td style="vertical-align:top"><p>3 (3.1)</p></td><td style="vertical-align:top"><p>3 (2.7)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of Response (DOR)</strong> (months)<sup>b</sup></p><p>Median (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>NE (28.3, NE)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>DOR if best response is sCR<sup>a</sup> (months)</p><p>Median<sup> </sup>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>NE (28.3, NE)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>Time to Response (months)</strong></p><p>Median (Range)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.95 (0.9; 10.7)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>MRD negativity rate</strong> n (%)<sup>c</sup></p></td><td style="vertical-align:top"><p>56 (57.7)</p></td><td style="vertical-align:bottom"><p>56 (49.6)</p></td></tr><tr><td style="vertical-align:top"><p>95% CI (%)</p></td><td style="vertical-align:top"><p>(47.3, 67.7)</p></td><td style="vertical-align:bottom"><p>(40.0, 59.1)</p></td></tr><tr><td style="vertical-align:top"><p>MRD negative patients with sCR n (%)<sup>c</sup></p></td><td style="vertical-align:top"><p>42 (43.3)</p></td><td style="vertical-align:top"><p>42 (37.2)</p></td></tr><tr><td style="vertical-align:top"><p>95% CI (%)</p></td><td style="vertical-align:top"><p>(33.3, 53.7)</p></td><td style="vertical-align:top"><p>(28.3, 46.8)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>CI=confidence interval; MRD= Minimal Residual Disease; NE= not estimable</p><p>Notes: Based on a median duration of follow up of 28&nbsp;months</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; All complete responses were stringent CRs.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp; The estimated DOR rate was 60.3% (95% CI: 49.6%, 69.5%) at 24 months and 51.2% (95% CI: 39.0%, 62.1%) at 30 months.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp; Only MRD assessments (10<sup>-5</sup> testing threshold) within 3&nbsp;months of achieving CR/sCR until death / progression / subsequent therapy (exclusive) are considered. All complete responses were stringent CRs. MRD negativity rate [(%) 95% CI] in evaluable patients (n=61) was 91.8% (81.9%, 97.3%).</p></td></tr></tbody></table><p>&nbsp;</p><p><em>CARTITUDE-4 (Study MMY3002)</em></p><p>MMY3002 is a Phase&nbsp;3 randomised, open label, multicentre trial evaluating the efficacy of CARVYKTI for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma, who previously received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. A total of 419&nbsp;patients were randomised to received either a sequence of apheresis, bridging therapy, lymphodepletion and CARVYKTI (n=208) or standard of care which included physician&rsquo;s choice of daratumumab, pomalidomide and dexamethasone or bortezomib, pomalidomide and dexamethasone (n=211).</p><p>&nbsp;</p><p>The trial excluded patients with known active or prior history of central nervous system involvement, clinical signs of meningeal involvement of multiple myeloma, a history of Parkinson&rsquo;s disease or other neurodegenerative disorder, previous exposure to other anti‑BCMA treatments or CAR‑T cell therapy directed at any target, allogenic stem cell transplant within 6&nbsp;months before apheresis or ongoing treatment with immunosuppressants, or autologous stem cell transplant within 12&nbsp;weeks before apheresis.</p><p>&nbsp;</p><p>Of the 419&nbsp;patients who were randomised (208 to CARVYKTI and 211 to standard of care), 57% were male, 75% were caucasian, 3% were black or african-american, and 7% were hispanic or latino. The median patient age was 61&nbsp;years (range: 28 to 80&nbsp;years). Patients had received a median of 2 (range: 1 to 3) prior lines of therapy and 85% of patients had received prior autologous stem cell transplantation (ASCT). Ninety-nine percent of patients were refractory to their last line of prior therapy. Forty-eight percent were refractory to a proteasome inhibitor (PI) and 100% were refractory to an immunomodulatory agent.</p><p>&nbsp;</p><p>All 208&nbsp;patients randomised to the CARVYKTI arm underwent apheresis. Following apheresis and prior to administration of CARVYKTI, all 208 randomised patients received protocol‑mandated bridging therapy (standard of care). Of these 208&nbsp;patients, 12 were not treated with CARVYKTI due to progressive disease (n=10) or death (n=2), and 20 progressed prior to infusion with CARVYKTI but were able to receive CARVYKTI as subsequent therapy.</p><p>&nbsp;</p><p>In the 176&nbsp;patients that received CARVYKTI as study treatment, the median time from the day after receipt of apheresis material at manufacturing facility to release of product for infusion was 44&nbsp;days (range: 25 to 127&nbsp;days) and the median time from first apheresis to CARVYKTI infusion was 79&nbsp;days (range: 45&nbsp;days to 246&nbsp;days).</p><p>&nbsp;</p><p>CARVYKTI was administered as a single IV infusion 5 to 7&nbsp;days after the start of a lymphodepleting chemotherapy (cyclophosphamide 300&nbsp;mg/m<sup>2</sup> intravenously daily and fludarabine 30&nbsp;mg/m<sup>2</sup> intravenously daily for 3&nbsp;days) at a median dose of 0.71&times;10<sup>6</sup> CAR-positive viable T-cells/kg (range: 0.39 to 1.07&times;10<sup>6</sup>&nbsp;cells/kg).</p><p>&nbsp;</p><p>The primary efficacy measure was progression-free survival (PFS) analysed based on the Intent-To-Treat Analysis Set (Table&nbsp;8 and Figure&nbsp;1). After a median follow-up of 15.9&nbsp;months, median PFS was 11.8&nbsp;months (95% CI: 9.7, 13.8) for the standard of care arm and NE (95% CI: 22.8, NE) for the CARVYKTI arm (Hazard ratio: 0.26 [95% CI: 0.18, 0.38]).&nbsp;The estimated PFS rate at 12 months was 75.9% (95% CI: 69.4%, 81.1%) in the CARVYKTI arm and 48.6% (95% CI: 41.5%, 55.3%) in the standard of care arm. In the CARVYKTI arm, the estimated median duration of response (DOR) has not been reached. In the standard of care arm, the estimated median DOR was 16.6 months (95% CI: 12.9, NE). After a median follow-up of 15.9 months, median overall survival (OS) was NE (95% CI: NE, NE) for the CARVYKTI arm and 26.7 months (95% CI: 22.5, NE) for the standard of care arm (Hazard ratio: 0.78 [95% CI: 0.50, 1.20]; p-value = 0.2551). Updated OS results with a median follow-up of 28.7 months are presented in Table 8 and Figure 2.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:bottom"><p><strong>Table&nbsp;8:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy results for Study MMY3002 (Intent-To-Treat Analysis Set)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>CARVYKTI</strong><strong> (N=208)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Standard of Care </strong></p><p><strong>(N=211)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Progression-Free Survival<sup>a</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Number of events, n (%)</p></td><td style="vertical-align:top"><p>65 (31.3)</p></td><td colspan="2" style="vertical-align:top"><p>122 (57.8)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Median, months [95% CI]<sup>b</sup></p></td><td style="vertical-align:top"><p>NE [22.8, NE]</p></td><td colspan="2" style="vertical-align:top"><p>11.8 [9.7, 13.8]</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Hazard ratio [95% CI]<sup>c</sup></p></td><td colspan="3" style="vertical-align:top"><p>0.26 [0.18, 0.38]</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; p-value<sup>d</sup></p></td><td colspan="3" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Complete Response or Better Rate<sup>a</sup>, % [95% CI]</strong></p></td><td style="vertical-align:top"><p>73.1 [66.5, 79.0]</p></td><td colspan="2" style="vertical-align:top"><p>21.8 [16.4, 28.0]</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; p-value<sup>e</sup></p></td><td colspan="3" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall Response Rate (ORR)<sup>a</sup>, % [95% CI]</strong></p></td><td style="vertical-align:top"><p>84.6 [79.0, 89.2]</p></td><td colspan="2" style="vertical-align:top"><p>67.3 [60.5, 73.6]</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; p-value<sup>e</sup></p></td><td colspan="3" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall MRD Negativity Rate, % [95% CI]</strong></p></td><td style="vertical-align:top"><p>60.6 [53.6, 67.3]</p></td><td colspan="2" style="vertical-align:top"><p>15.6 [11.0, 21.3]</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; &nbsp;p-value<sup>f</sup></p></td><td colspan="3" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall Survival (OS)</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Number of events, n (%)</p></td><td colspan="2" style="vertical-align:top"><p>48 (23.1)</p></td><td style="vertical-align:top"><p>77 (36.5)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Median, months [95% CI]<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>NE [NE, NE]</p></td><td style="vertical-align:top"><p>NE [34.0, NE]</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Hazard ratio [95% CI]<sup>g</sup></p></td><td colspan="3" style="vertical-align:top"><p>0.57 [0.40, 0.83]</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>NE=not estimable; CI=confidence interval; MRD=minimal residual disease</p><p>Notes: PFS, response rate, and MRD negativity rate based on a median duration of follow up of 15.9&nbsp;months. Overall survival based on a median duration of follow-up of 28.7 months.</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; Per the International Myeloma Working Group (IMWG) consensus, as assessed by computerised algorithm</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp; Kaplan-Meier estimate</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp; Based on a stratified Cox proportional hazards model, including only PFS events that occurred more than 8&nbsp;weeks post-randomisation. A hazard ratio &lt;1 indicates an advantage for the CARVYKTI arm. For all stratified analyses, stratification was based on investigator&rsquo;s choice (PVd or DPd), ISS staging (I, II, III) and number of prior lines (1 vs. 2 or 3) as randomised.</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp;&nbsp; Stratified weighted log-rank test (weight of 0 in the log-rank statistic for the first 8&nbsp;weeks post-randomisation, and 1 afterwards)</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp;&nbsp; Stratified Cochran-Mantel-Haenszel Chi-Squared test</p><p><sup>f</sup>&nbsp;&nbsp;&nbsp;&nbsp; Fisher&rsquo;s exact test</p><p><sup>g</sup>&nbsp;&nbsp;&nbsp;&nbsp; Based on a stratified Cox proportional hazards model. A hazard ratio &lt;1 indicates an advantage for the CARVYKTI arm.</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>Figure&nbsp;1: Kaplan-Meier Curve of PFS in Study MMY3002 (Intent-To-Treat Analysis Set)</strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_4" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:381pt;height:328.2pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/RAljasmi/AppData/Local/Temp/2/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="789" height="556" alt="" vspace="0" hspace="0" border="0" style="width:789px;height:556px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/RAljasmi/AppData/Local/Temp/2/msohtmlclip1/01/clip_image002.png" /></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Note: Intent-to-treat analysis set consists of subjects who were randomised in the study.</p></td></tr></tbody></table><p>&nbsp;</p><p>Of the 176&nbsp;patients who received CARVYKTI as study treatment, the median progression‑free survival (PFS) was not estimable (95% CI: not estimable, not estimable) with a 12&nbsp;months PFS rate of 89.7%. The overall response rate (ORR) in these patients was 99.4% (95% CI: 96.9%, 100.0%). The rate of CR/sCR was 86.4% (95% CI: 80.4%, 91.1%).</p><p><strong>Figure 2: </strong><strong>Kaplan-Meier Curve of OS in Study MMY3002 (Intent-To-Treat Analysis Set)</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Picture_x0020_6" o:spid="_x0000_s1026" type="#_x0000_t75" style='position:absolute;
  margin-left:0;margin-top:18.25pt;width:417.4pt;height:5in;z-index:251659264;
  visibility:visible;mso-wrap-style:square;mso-width-percent:0;
  mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
  mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
  mso-position-horizontal:left;mso-position-horizontal-relative:margin;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
  mso-height-relative:page'>
  <v:imagedata src="file:///C:/Users/RAljasmi/AppData/Local/Temp/2/msohtmlclip1/01/clip_image003.png"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="margin"/>
 </v:shape><![endif]--><img width="557" height="480" alt="" vspace="0" hspace="0" border="0" style="width:557px;height:480px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/RAljasmi/AppData/Local/Temp/2/msohtmlclip1/01/clip_image004.png" /><!--[if gte vml 1]></o:wrapblock><![endif]--><br />Note: Intent-to-treat analysis set consists of subjects who were randomised in the study. Overall survival based on a median duration of follow-up of 28.7 months.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with CARVYKTI in all subsets of the paediatric population in multiple myeloma (see section&nbsp;4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>CARVYKTI pharmacokinetics (PK) was assessed in 97&nbsp;adult patients with relapsed or refractory multiple myeloma in Study MMY2001 receiving a single CARVYKTI infusion at the median dose of 0.71&nbsp;&times;&nbsp;10<sup>6</sup>&nbsp;CAR-positive viable T&nbsp;cells/kg (range: 0.51&nbsp;&times;&nbsp;10<sup>6</sup> to 0.95&nbsp;&times;&nbsp;10<sup>6</sup>&nbsp;cells/kg).</p><p>&nbsp;</p><p>Following a single infusion, CARVYKTI exhibited an initial expansion phase followed by a rapid decline and then a slower decline. However, high interindividual variability was observed.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:598px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;9:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Pharmacokinetic parameters of CARVYKTI in patients with multiple myeloma</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Summary Statistics</strong></p></td><td style="vertical-align:top"><p><strong>N=97</strong></p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> (copies/&micro;g genomic DNA)</p></td><td style="vertical-align:top"><p>Mean (SD), n</p></td><td style="vertical-align:top"><p>48692 (27174), 97</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>max</sub> (day)</p></td><td style="vertical-align:top"><p>Median (range), n</p></td><td style="vertical-align:top"><p>12.71 (8.73&nbsp;&ndash;&nbsp;329.77), 97</p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>0-28d</sub> (copies*day/&micro;g genomic DNA)</p></td><td style="vertical-align:top"><p>Mean (SD), n</p></td><td style="vertical-align:top"><p>504496 (385380), 97</p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>0-last</sub> (copies*day/&micro;g genomic DNA)</p></td><td style="vertical-align:top"><p>Mean (SD), n</p></td><td style="vertical-align:top"><p>1098030 (1387010), 97</p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>0-6m</sub> (copies*day/&micro;g genomic DNA)</p></td><td style="vertical-align:top"><p>Mean (SD), n</p></td><td style="vertical-align:top"><p>1033373 (1355394), 96</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>1/2</sub> (day)</p></td><td style="vertical-align:top"><p>Mean (SD), n</p></td><td style="vertical-align:top"><p>23.5 (24.2), 42</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>last</sub> (day)</p></td><td style="vertical-align:top"><p>Median (range), n</p></td><td style="vertical-align:top"><p>125.90 (20.04&nbsp;&ndash;&nbsp;702.12), 97</p></td></tr></tbody></table><p>&nbsp;</p><p>After the cell expansion, the persistence phase of the CARVYKTI was observed for all patients. At the time of analysis (n=65), the median time for CAR transgene levels in peripheral blood to return to the pre-dose baseline level was approximately 100&nbsp;days (range: 28-365&nbsp;days) post‑infusion. The PK of CARVYKTI was assessed in 176&nbsp;adult patients with lenalidomide refractory multiple myeloma in MMY3002 and were generally consistent with those in Study MMY2001.</p><p>&nbsp;</p><p>Detectable CARVYKTI exposures in bone marrow indicate a distribution of CARVYKTI from systemic circulation to bone marrow. Similar to blood transgene levels, bone marrow transgene levels declined over time and exhibited high interindividual variability.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>The pharmacokinetics of CARVYKTI (C<sub>max</sub> and AUC<sub>0-28d</sub>) were not impacted by age (range: 27‑78&nbsp;years, including patients &lt;&nbsp;65&nbsp;years of age (n=215; 64.8%), 65-75&nbsp;years (n=105; 31.6%) and&nbsp;&gt;&nbsp;75&nbsp;years of age (n=12; 3.6%).</p><p>&nbsp;</p><p>Similarly, the pharmacokinetics of CARVYKTI (C<sub>max</sub> and AUC<sub>0-28d</sub>) were not impacted by gender, body weight, and race.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>Renal impairment studies of CARVYKTI were not conducted. CARVYKTI C<sub>max</sub> and AUC<sub>0-28d</sub> in patients with mild renal dysfunction (60&nbsp;mL/min &le; creatinine clearance [CRCL] &lt;&nbsp;90&nbsp;mL/min) or moderate renal dysfunction (30&nbsp;mL/min &le; creatinine clearance &lt;&nbsp;60&nbsp;mL/min) were similar to patients with normal renal function (CRCL &ge;&nbsp;90&nbsp;mL/min).</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>Hepatic impairment studies of CARVYKTI were not conducted. CARVYKTI C<sub>max</sub> and AUC<sub>0-28d</sub> were similar in patients with mild hepatic dysfunction [(total bilirubin &le; upper limit of normal (ULN) and aspartate aminotransferase &gt; ULN) or (ULN &lt; total bilirubin &le;&nbsp;1.5&nbsp;times ULN)] and patients with normal hepatic function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>CARVYKTI comprises engineered human T cells; therefore, there are no representative <em>in vitro</em> assays, <em>ex vivo</em> models, or <em>in vivo</em> models that can accurately address the toxicological characteristics of the human product. Hence, traditional toxicology studies used for medicinal product development were not performed.</p><p>&nbsp;</p><p><u>Carcinogenicity and mutagenicity</u></p><p>No genotoxicity or carcinogenicity studies have been performed.</p><p>&nbsp;</p><p>The risk for insertional mutagenesis occurring during the manufacturing of CARVYKTI following transduction of autologous human T cells with an integrating lentiviral vector (LV) was assessed by evaluating the integration pattern of the vector in pre-infusion CARVYKTI. This genomic insertional site analysis was performed on CARVYKTI products from 7&nbsp;samples from 6&nbsp;multiple myeloma patients and from 3 samples from 3&nbsp;healthy donors. There was no evidence for preferential integration near genes of concern.</p><p>&nbsp;</p><p><u>Reproductive toxicology</u></p><p>No reproductive and developmental toxicity animal studies have been conducted with CARVYKTI.</p><p>No studies have been conducted to evaluate the effects of CARVYKTI on fertility.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cryostor CS5 (contains dimethyl sulfoxide)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                9 months.

Once thawed: maximum 2.5 hours at room temperature (20 °C to 25 °C). CARVYKTI infusion must be administered immediately after thawing and completed within 2.5 hours.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>CARVYKTI must be stored and transported in the vapour phase of liquid nitrogen (&le;&nbsp;-120&nbsp;&deg;C) and must remain frozen until the patient is ready for treatment to ensure viable cells are available for patient administration.</p><p>Thawed medicinal product must not be shaken, refrozen or refrigerated.</p><p>&nbsp;</p><p>Keep infusion bag in the aluminium cryo cassette.</p><p>For storage conditions after thawing of the medicinal product, see section&nbsp;6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ethylene vinyl acetate (EVA) infusion bag with sealed addition tube and two available spike ports containing either 30&nbsp;mL (50&nbsp;mL bag) or 70&nbsp;mL (250&nbsp;mL bag) of cell dispersion.</p><p>Each infusion bag is packed in an aluminium cryo cassette.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>CARVYKTI should not be irradiated as irradiation could inactivate the medicinal product.</p><p>&nbsp;</p><p><u>Precautions to be taken before handling or administering the medicinal product</u></p><p>CARVYKTI should be transported within the facility in closed, break-proof and leak-proof containers.</p><p>&nbsp;</p><p>This medicinal product contains human blood cells. Healthcare professionals handling CARVYKTI should take appropriate precautions (wearing gloves, protective clothing and eye protection) to avoid potential transmission of infectious diseases.</p><p>CARVYKTI must remain &le;&nbsp;-120&nbsp;&deg;C at all times, until the content of the bag is thawed for infusion.</p><p><em>&nbsp;</em></p><p><u>Preparation prior to administration</u></p><p>The timing of CARVYKTI thaw and infusion should be coordinated; the infusion time should be confirmed in advance, and the start time for thaw must be adjusted so that CARVYKTI is available for infusion when the patient is ready. Once thawed, the medicinal product should be administered immediately and the infusion should be completed within 2.5&nbsp;hours.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prior to CARVYKTI preparation, patient identity should be confirmed by matching the patient&rsquo;s identity with the patient identifiers on the CARVYKTI cryo cassette and Lot Information Sheet. The CARVYKTI infusion bag should not be removed from the cryo cassette if the information on the patient-specific label does not match the intended patient.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Once patient identification is confirmed, the CARVYKTI infusion bag should be removed from the cryo cassette.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The infusion bag should be inspected for any breaches of container integrity such as breaks or cracks before and after thawing. Do not administer if the bag is compromised and contact <strong>Janssen-Cilag</strong> <strong>International NV</strong>.</p><p><strong>&nbsp;</strong></p><p><em>Thawing</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The infusion bag should be placed inside a sealable plastic bag prior to thawing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CARVYKTI should be thawed at 37&nbsp;&deg;C&plusmn;2&nbsp;&deg;C using either a water bath or dry thaw device until there is no visible ice in the infusion bag. Total time from start of thaw until completion of thawing should be no more than 15&nbsp;minutes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The infusion bag should be removed from the sealable plastic bag and wiped dry. The contents of the infusion bag should be gently mixed to disperse clumps of cellular material. If visible cell clumps remain, the contents of the bag should continue to be gently mixed. Small clumps of cellular material should disperse with gentle manual mixing. CARVYKTI must not be pre-filtered into a different container, washed, spun down, and/or resuspended in new media prior to infusion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Once thawed, the medicinal product should not be re-frozen or refrigerated.</p><p>&nbsp;</p><p><em>Administration</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CARVYKTI is for autologous single use only.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prior to infusion and during the recovery period, ensure tocilizumab and emergency equipment are available for use.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confirm the patient&rsquo;s identity with the patient identifiers on the CARVYKTI infusion bag and Lot Information Sheet. Do not infuse CARVYKTI if the information on the patient-specific label does not match the intended patient.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Once thawed, the entire contents of the CARVYKTI bag should be administered by intravenous infusion within 2.5&nbsp;hours at room temperature (20&nbsp;&deg;C to 25&nbsp;&deg;C), using infusion sets fitted with an in-line filter. The infusion usually takes less than 60&nbsp;minutes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do NOT use a leukodepleting filter.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently mix the contents of the bag during CARVYKTI infusion to disperse cell clumps.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After the entire content of the product bag is infused, flush the administration line, inclusive of the in-line filter, with sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection to ensure all medicinal product is delivered.</p><p>&nbsp;</p><p><u>Precautions to be taken for the disposal of the medicinal product</u></p><p>Unused medicinal product and all material that has been in contact with CARVYKTI (solid and liquid waste) should be handled and disposed of as potentially infectious waste in accordance with local guidelines on handling of human-derived material.</p><p>&nbsp;</p><p><u>Measures to take in case of accidental exposure</u></p><p>In case of accidental exposure local guidelines on handling of human-derived material should be followed. Work surfaces and materials which have potentially been in contact with CARVYKTI must be decontaminated with appropriate disinfectant.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>